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Markov models are a major class within the system of multi-state models for the
analysis of lifetime or event-time data. Applications abound, including the estimation
of lifetime of ultra-cold neutrons, the bias correction of the apparent magnitude
distribution of the stars in a certain area of the sky, and the survival analysis of
clinical trials. This thesis addresses some of the problems arising in the analysis of
right-censored lifetime data. Clinical trials are used as examples to investigate these
problems. A Markov model that takes a patient’s disease development into account
for the analysis of right-censored data was first constructed by Fix and Neyman
(1951). The Fix-Neyman (F-N) model is a homogeneous Markov process with two
transient and two absorbing states that describes a patient’s status over a period of
time during a cancer clinical trial.
This thesis extends the F-N model by assuming the transition rates (hazard
rates) to be both state and time dependent. Recurrent transitions between relapse
and recovery are allowed in the extended model. By relaxing the condition of time-
independent hazard rates, the extension increases the applicability of the Markov
models. The extended models are used to compute the model survival functions,
cumulative hazard functions that take into consideration of right censored obser-
vations as it has been done in the celebrated Kaplan-Meier estimator. Using the
Fix-Neyman procedure and the Kolmogorov forward equations, closed-form solu-
tions are obtained for certain irreversible 4-state extended models while numerical
solutions are obtained for the model with recurrent events. The 4-state model is
motivated by an Aplastic Anemia data set. The computational method works for
general irreversible and reversible models with no restriction on the number of states.
Simulations of right-censored Markov processes are performed by using a se-
quence of competing risks models. Simulated data are used for checking the perfor-
mance of nonparametric estimators for various sample sizes. In addition, applying
Aalen’s (1978) results, estimators are shown have asymptotic normal distributions.
A brief review of some of the literature relevant to this thesis is provided. Ref-
erences are readily available from a vast literature on the survival analysis including
many text books. General Markov process models for survival analysis are described,
e.g., in Andersen, Borgan, Gill and Keiding (1993).
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when T = ∞, the red solid line is Ŝ(t) when T = 5, the red dashed line is Ŝ(t)
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Statistical analyses of lifetime data are routinely carried out in a broad spec-
trum of scientific disciplines. Depending on the area of applications, a lifetime could
be the lifetime of a human being or an item produced in a factory, or the doubling
time of the size of a malignant tumour, or the survival time of a cancer patient
measured fom the time of diagnosis, or the time to disintegration of an ultra-cold
neutron, or the time to move to another house, and numerous others. In other words,
a lifetime is considered as a waiting time to an event under study which is measured
from a well-defined initial condition of a subject under study to the time of occur-
rence of a specific event of interest. Thus, a lifetime, a survival time and an event
time will be used interchangeably in this thesis.
Of particular interest in the statistical analysis of lifetime data are the study of
the survival function, life expectation function, failure rate (hazard rate), cumulative
hazard rate function. Under some conditions, these functions provide alternative
ways of describing the distribution of a lifetime. Widely used life tables are con-
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structed that display simultaneously the estimates of these functions based on data
sets of lifetimes.
Collection of lifetime data is by no means simple. The method of collection
determines how a model for lifetime data should be constructed for statistical anal-
ysis. Due to technical difficulties that vary with the field of applications, sampling
limitations, and cost considerations, it is rather unusual to obtain a data set that
has all completely observed lifetimes. Typically some of the lifetime observations in
the data set can only be partially recorded. Statistical theory shows that partially
observed data must be included in the statistical analysis. Otherwise the findings
would be biased. Inclusion of partially observed lifetimes in the analysis depends on
the sampling plan for data collection and the model constructed for the data.
Depending on the particular sampling plan employed, an observed lifetime can
be incomplete in the sense that it is censored, randomly truncated, length biased,
size biased, interval censored or possibly other forms of incompleteness. There is
a vast statistical literature dealing with statistical theory, model constructions and
applications of incomplete lifetimes.
This thesis addresses some of the statistical problems arising in right-censored
data. One of the most widely used model is the traditional right-censoring models
(to be called right-censoring model for short) for survival analysis which refers to
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the joint distribution of (V, δ) defined in (2.1) under the stochastic independence
assumption of X and C. Some (Meira-Machado et al. (2009) [37]) call it a mortality
model where the concern is with the time-to-death of a patient regardless a patient’s
disease development leading to the end point of death. A stochastic model that
takes patient’s disease development into account for the analysis of right-censored
data was constructed by Fix and Neyman (1951) [23]. The Fix-Neyman (F-N) model
is a homogeneous Markov process with two transient and two absorbing states that
describes a patient’s status during a cancer clinical trial where the statuses are in-
remission (or recovery), relapse, death and loss to follow up. When casting the
right-censoring model into a 3-state Markov process with one transient state and two
absorbing states of death and loss to follow up, the right-censoring model becomes
a special case of the F-N model. The difference between the models is that all of
the transition rates (hazard rates) in the F-N model are assumed to be independent
of the time t while those in the right-censoring model can be both state and time
dependent.
In this thesis, we extend the F-N model by letting all of the transition rates
(risks) to be both state and time dependent. That is, we extend the Fix-Neyman
model to a non-homogeneous finite-state Markov process. The extension is necessary
as it is well known that in many applications, time-independent hazard rates do not
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fit the data. A glaring example is the survival function of human lifetimes shown in
Figure 1.1. The survival curve does not have an exponential distribution. It would
be too good to be true if the survival curve had an exponential distribution with
age-independent failure.

















Figure 1.1: Comparison of an exponential survival function and the survival function
of lifetime obtained by converting the life expectancy function given in the United
States Life Tables 2008 (Arias (2012) [10]). The red line is the exponential survival
function. The black line is the actual survival function of lifetime.
Applying the Fix-Neyman (F-N) procedure, in Section 2.2 we derive the sur-
vival function of an individual that takes into account right-censored observations
(due to the risk of loss to follow-up). This result answers an identifiability prob-
lem, namely that from right-censored non-homogeneous Markov process, the sur-
vival function of an individual under study is identifiable. Although identifying
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the survival function using the F-N procedure is elegantly simple, computational
complexities increase with the number of states in the model. For instance, it is
straightforward to compute the survival function in the right-censoring model, but
for the extended F-N model with time and state-dependent transition rates, an ex-
plicit analytical solution for the survival function is only available in some special
cases. For more complicated transition patterns, we obtained the solutions for the
survival function numerically.
Markov models have been used broadly in the analysis of lifetime data. General
Markov process models for survival analysis are succinctly described in Andersen,
Borgan, Gill and Keiding (Chapter III.1.2, 1993) [7]. The Fix-Neyman (1951) [23]
paper was discussed in early years after its publication, e.g. Chiang (1968) [14], Cox
(1972) [18], Prentice and Kalbfleisch (1978) [43]. But it seems to have disappeared
in more recent literature. As far as we know, the F-N procedure is hardly used.
Although the F-N procedure may not be needed for some Markov models with 2
or 3 states and simple transition paths, for more states with complicated transition
paths, the advantage of the F-N procedure becomes clear.
Chapter 2 gives a brief review of some of the literature relevant to this thesis.
Section 2.2 presents the F-N procedure and compares it with the usual method of
calculating the survival function in the right-censoring model. Details can be found
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in Yang (2013) [50]. Section 2.3 shows that technically the Markov models considered
in this thesis unify the study of the survival function for some important multi-state
models such as the multiple decrement model, the illness-death model, Chiang’s
staging model, the progressive model and the F-N model. The section also includes
a review of an extension to models for bivariate survival lifetimes. Section 2.4 deals
with various approaches to estimation in Markov multi-state models. Parametric,
nonparametric estimation and regression problems are reviewed separately. Section
2.5 notes some more recent results on non-Markovian models.
Chapter 3 is devoted to the construction of an irreversible Markov model. The
model is motivated by an clinical trial of patients with Aplastic Anemia(AA). We
use an irreversible 4-state non-homogeneous Markov model ξo to describe the pro-
gression of a patient with AA. This is covered in Section 3.2. Section 3.3 gives a
construction of the model by using competing risks at every transition time. The
construction is needed for estimation and simulation. In Section 3.4, we state the es-
timation problems of the cumulative hazard functions, transition probabilities, and
survival function and explain the available data. Section 3.5 carries out the es-
timation problems. Section 3.5.1 constructs the estimators for cumulative hazard
functions. Section 3.5.2 deals with estimation of transition probabilities. The es-
timation requires solving the Kolmogorov forward equations for explicit analytical
6
forms of the transition probabilities. Solutions are obtained. Section 3.5.3 derives
the model solution for the sought-after survival function S(t) which is a function
of transition probabilities obtained in Section 3.5.2. the estimator of the survival
function is obtained whose distributional properties are checked by simulation data.
Section 3.7 shows the estimator of the cumulative hazard function constructed in
this thesis is identical to that given by Aalen (1978b) [2]. Therefore the asymptotic
properties established by Aalen apply to our estimators as well.
Chapter 4 contains the simulation of irreversible Markov processes. Simulated
data are used to examine the distributional properties of the estimators developed
in Chapter 3. Results are presented in Section 4.2. In Section 4.3, we carry out
goodness of fit testing of the model by statistical hypothesis testing using both a
modified Kolmogorov-Smirnov test and a chi-squared test.
Chapter 5 is concerned with estimation and simulation in reversible Markov
models. The treatment is similar but not identical to that for irreversible Markov
models. Only differences between the two are discussed.
Chapter 6 concludes this thesis.
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Chapter 2: Literature Review
2.1 Introduction
Markov models are a major part of the multi-state models. The review is
primarily on Markov multi-state models.
Section 2.2 discusses the F-N procedure and compares it with the usual method
of calculating the survival function in the traditional right-censoring model. Stochas-
tic models for lifetime data and statistical estimation are reviewed separately in
Sections 2.3 and 2.4 respectively. Section 2.5 notes some recent development on
non-Markovian models. Section 2.6 reviews several well-known models for recurrent
event analysis.
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2.2 Comparison of the Fix-Neyman Model and the Right-Censoring
Model
It is convenient to compare the F-N model and the right-censoring model by
an example.
A prototype example of right-censored data is the collection of survival times
from a clinical trial of cancer patients who have received a certain method of treat-
ment. After the treatment, each patient is followed up over a period of time. If the
death occurs in the followup period, his/her survival time can be determined. Other-
wise, it is only known that the survival time is larger than the length of the followup
period. However, the length of the follow up period varies with each patient. This
could be due to a patient’s withdraw from the clinical trial (loss to followup), or the
termination of the clinical trial, or possible other reasons. Formally, let X denote the
survival time of a patient and C the length of his/her followup time. The observable
data on X are given by a pair of random variables
V = min(X,C) and δ (2.1)
where δ = I[X ≤ C] is an indicator which is one if X ≤ C and zero otherwise. Only
if δ = 1, is X completely observable. When δ = 0, we say X is right-censored by
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C. Under the assumption of stochastic independence of X and C, (2.1) is called the
(classical) right-censoring model.
Thus instead of a direct measurement of X, we can only observe V and δ.
The question arising is whether the survival function S(t) = P [X > t] for all t can
be identified from the joint distribution of V and δ. The answer is affirmative if
we assume that X and C are stochastically independent random variables. (To be
correct, we also require that the range of C is larger than that of X for nonparametric
estimation of the survival function). Under the independence assumption, (2.1) is
called a right-censoring model of X. The right-censored data from all n patients are
(Vj, δj) j = 1, . . . , n. (2.2)
The right censored data are broadly used in the estimation of the survival func-
tion of a patient as well as in other scientific investigations. Asymptotic properties
of the celebrated Kaplan-Meier (K-M) nonparametric estimator (Kaplan and Meier
(1958) [32]) of S have been established under the right-censoring model (2.1).
The F-N model (1951) [23] was constructed for analyzing survival times of
patients who received a particular treatment of breast cancer. In calculating the
survival function of a patient, Fix and Neyman took into account of the available
data on each patient’s status with regard to relapse, recovery, loss to followup and
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death. Let ξo(t) represent the status of a patient at time t. Fix and Neyman
constructed a model {ξo(t) : 0 ≤ t ≤ T )} where a patient’s changes in status are
governed by a 4-state homogeneous Markov process, and T is the termination time
of the clinical trial. The four states are:
S0: a patient has completed treatment and is in remission
S1: a patient has relapsed
S2: a patient is dead
S3: a patient is lost to followup
At any time t, the infinitesimal matrix Qo and possible transitions of a patient
are shown in Figure 2.1 with transition rates q01, q02, q03 from S0 to S1, S2, S3,
Qo =
(q00 q01 q02 q03
0 q11 q12 q13
0 0 0 0
0 0 0 0
) S0 S1
S2 S3
Figure 2.1: F-N model.
respectively and q12, q13 from S1 to S2, S3, respectively. Note that Fix and Neyman
[23] allow the transition rate q10 > 0 from S1 to S0. For simplicity of discussing the
F-N procedure, a simpler version of setting q10 = 0 is used in Figure 2.1 (see Yang
[50]).
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Over the course of the clinical trial, a patient can experience one of the following
four possible transition paths:
(1) S0 → S1 → S2
(2) S0 → S1 → S3
(3) S0 → S2
(4) S0 → S3
The right-censoring in the F-N model is much more complicated than that of the
right-censoring model (2.1). Note that path (2) or (4) results in a right-censored
survival time, that is, knowing only the survival time Xo > t, while path (1) or (3)
gives a complete observation of survival time. For simplicity of illustration, we set
T =∞. The survival function of Xo of a patient in the presence of loss to followup
can be identified in the Markov process ξo by
So(t) = P [Xo > t] = 1− P [ξo(t) = 2|ξo(0) = 0], t ≥ 0. (2.3)
Fix and Neyman showed that the (net) survival function S of a patient can
be obtained by by introducing another Markov process {ξ(t) : t ≥ 0} with states
S0, S1 and S2, where ξ(t) represents the status of a patient in the 3-state Markov
12
process with the risks q03 and q13 to loss-to-followup eliminated, and the transition







Figure 2.2: F-N model with censoring state eliminated.
The infinitesimal matrix Q and possible transitions in this Markov process are
shown in Figure 2.2. The true survival function S is given by
S(t) = P [X > t] = 1− P [ξ(t) = 2|ξ(0) = 0], t ≥ 0 (2.4)
This establishes the identifiability of S from the F-N model.
To compare the F-N model with the right-censoring model, we reformulate
the right censoring model (2.1) as a 3-state Markov process, {ηo(t) : t ≥ 0} where
ηo(t) represents the status of a patient at time t. The three states are S0, S2, S3.
At any given time t, the possible transitions of a patient are shown in Figure 2.3
with transition rates q02 and q03 from S0 to S2 and S3 respectively. Over the time of
clinical trial, a patient takes one of the two possible transition paths:








Figure 2.3: Right-censoring model.
(2) S0 → S3
It is easy to show that the joint distribution of the right-censored observations
V = min(X,C) and δ in (2.1) correspond to that of the Markov process ηo by
P [V ≤ t, δ = 1] = P [ηo(t) = 2|ηo(0) = 0] (2.5)
P [V ≤ t, δ = 0] = P [ηo(t) = 3|ηo(0) = 0] (2.6)
Here, we take the hazard rates of X and C to be q02 and q03 respectively. To have
exact correspondence, we can assume that q02 and q03 are time-dependent. To identify
the survival function S using the F-N procedure is to derive it from another Markov
process,{η(t) : t ≥ 0} which is obtained by eliminating the risk q03 of loss-to-followup
in the process ηo but keeping the same risk q02 for S2. The process η has only one
transient state S0 and one absorbing state S2. It is trivial to compute the survival
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function S. It is given by
S(t) = P [X ≥ t] = P [η(t) = 0|η(0) = 0] (2.7)
For computing the survival function that is free of right censoring, Neyman (1951)
[23] [40] introduced the notion of crude and net survival probabilities in his discussion
of an illness and death model. The survival function So (see (2.3)) computed from
the F-N model for the crude data is called crude survival function. The sought-after
survival function S (see (2.4)) that is free from the risk of right-censoring is called the
net survival function. Identifying the survival function in the classical right-censoring
model is the same problem that Fix and Neyman investigated but for more general
right-censoring Markov models.
The F-N model includes the relapse information in the estimation of the survival
function, which is a better utilization of the available data than that of the classical
right-censoring model in (2.1). However it increases the complexity of the censoring
patterns and computations. Fix and Neyman obtained an explicit solution for S for
constant transition rates and carried out parametric estimation of S.
With the F-N procedure we can unify the method for identifying and comput-
ing survival probabilities for a large class of Markov multi-state models with time and
state dependent transition rates. However the computational complexities increase
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quickly with the increase of the number of states. We are able to obtain closed-form
solutions only in special cases. This is shown in the derivation of closed-form solu-
tions for transition probabilities and survival function for irreversible 4-state Markov
models (see Figure 2.4). For reversible 4-state Markov models (see Figure 2.5), we
developed numerical methods to obtain the solutions. The numerical methods can
be used for general Markov models.
Q =
q00(t) q01(t) q02(t) q03(t)0 q11(t) q12(t) q13(t)
0 0 0 0




Figure 2.4: Irreversible model.
Q =
q00(t) q01(t) q02(t) q03(t)q10(t) q11(t) q12(t) q13(t)
0 0 0 0




Figure 2.5: Reversible model.
2.3 Absorbing Markov Multi-state Models
A multi-state model is a stochastic process, ξ = {ξ(t) : t ≥ 0}, that de-
scribes the transitions of a study subject from one state to another over a period
of observation. Multi-state models are used extensively in science and engineering
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especially in biomedical research such as observing the status of patients over time
in a clinical trial. There are a multiple number of states that a patient may advance
to before reaching the end point (the event of interest). When such change data
are available in the trial, multi-state models take into account of these changes in
the computation and estimation of a patient’s survival function, cumulative hazard
function and others. Finite state absorbing Markov processes play important roles
in multi-state models. One of the advantages of absorbing Markov models is that
the survival function of a subject under study is identifiable because the Markovian
property presupposes that the competing risks at every transition are stochastically
independent. Tsiatis (1975) [49] gave an example of nonindentifiable (net) survival
functions in a multiple decrement model with dependent competing risks.
For short, we shall refer to absorbing Markov multi-state models as Markov
models. In Section 2.5 some non-Markov models are presented. Many commonly used
models for survival analysis are Markov models. These models differ by the number
of transient states and absorbing states, the transition paths and the assumptions of
the transition rates as deemed appropriate for applications. For example, the right-
censoring model (see (2.3)) has one transient state (alive) and two absorbing states
(death and loss to followup). Multiple decrement models (see (2.6)) (commonly
called competing risks models) are perhaps the earliest extension of right-censoring
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models which have one transient state (alive) and a finite number of absorbing states
for different causes of death. The simple illness and death model (e.g., Andersen and
Keiding (2002) [9], PROVA Study Group (1991) [29]) (see (2.7)) has two transient
states (healthy, illness) and one absorbing state (death). Chiang’s multiple staging
model (1980)[15] (see (2.8)) has k transient states representing different stages of
a progressive disease, and one absorbing state (death). A special case of the k-
progressive model (see (2.9)), the F-N model (see (2.1)), has two transient states
(recovery, relapse) and two absorbing states (death, loss to followup).
S0
S1 S2 . . . Sk
Figure 2.6: Transitions in the multiple decrement model.
S0 S1
S2
Figure 2.7: Transitions in the simple illness-death model.
Suppose a Markov model {ξ(t) : t ≥ 0} is a (k + 1)-state irreversible model.
Let qij denote the transition rate of an individual moving from state i to state j for
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S0 S1 . . . Sk−1
Sk
Figure 2.8: Transitions in Chiang’s multi-staging model.
0 1 . . . k
Figure 2.9: Transitions in the k-progressive model.
all states i, j. Then its infinitesimal matrix is given by
Q =

q00 q01 · · · · · · · · · q0k
0 q11 q12 · · · · · · q1k







0 0 0 0 0 0
 (2.8)
One sees that the qij below the diagonal are zero and the transition paths are in
one direction and irreversible (e.g Figure 2.4). Then the transition probabilities can
be solved recursively by using the Chapman-Kolmogorov equations. The survival
function can then be solved explicitly:
S(t) = P [X > t] = P [ξ(t) 6= k|ξ(0) = 0]. (2.9)
Calculation of the transition probabilities from the given transition rates are of in-
dependent interest in survival analysis.
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Chiang (1964, 1968) [13][14] extended the F-N model of two transient and two
absorbing states by including more transient and absorbing states in the model.
Results obtained by Chiang include explicit solutions for the transition probabilities
and multiple transition probabilities. In the special case of multiple decrement model,
explicit formulas for the crude and net survival probabilities are available (Chiang,
Chapter 11, 1968 [14]) where the transition rates are assumed to be a product cijλ(t)
of positive constants cij and a hazard rate function, λ(t) where λ(t) is a function of
the time t but independent of states for all i, j. Note that this model includes the
Cox regression model as a special case.
Chiang’s multi-staging model was generalized by J.Q. Fang in his unpublished
Ph.D thesis (1985) [21]. The generalization allows any finite number of transient
states and absorbing states. Fang’s model deals with time-dependent covariates
under the assumption of proportional hazards. The baseline hazard is assumed to
have log-linear form. See Section 2.4.3.
In the models discussed so far, the interest is in the survival time distribution
of a single individual. Due to possible dependence of the survival times of the study
subjects, there are many practical problems that require modeling of bivariate sur-
vival times (X1, X2) of two subjects, X1 and X2 (Freund 1961 [24], Marshall and
Olkin 1967 [35]), such as the survival times of twins, or the times to loss of hearing
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of each of the two ears, or the failure times of two related components of a system
in engineering reliability. The structure of the model is shown in Figure 2.10. Ex-
tensions to the two classical models includes Kvam and Samaniego (1997) [33] which
considers a generalization to k dimensions.
Q =
q00 q01 q02 00 q11 0 q13
0 0 q22 q23
0 0 0 0
 S0: Both alive
S1: Individual A failed
S2: Individual B failed
S3: Both failed
Figure 2.10: Transitions in the bivariate model.
2.4 Approaches to Estimation in Markov Multi-state Models
As noted before, in the context of multi-state models, our Markov models
always refer to absorbing Markov processes. Also hazard rate functions or transition
rate functions are referred to as hazard functions or transition rates respectively.
Typically Markov models are defined by specifying the transition rates qij(t),
i, j ∈ S. The transition rates are unknown and to be estimated from the data. The
literature on the estimation is huge and there are plenty of books on the subject, e.g.
Andersen (1997) [6], Andersen et al.(1993) [7], Kalbfleisch and Prentice (2002) [31]
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and Collett (2003) [16], to name a few. Our review is necessarily narrowly focused
on those more closely related to this thesis. We look at some of the very important
results in each of the three categories: parametric, nonparametric and regression
estimation.
2.4.1 Parametric Estimation
Estimation of constant transition rates in the homogeneous Markov models are
fairly well-developed. Maximum likelihood estimates (MLE) for the staging model
with constant transition rates are given in Chiang (1980) [15]. MLE under the F-N
model with covariates are obtained by Beck (1979) [11] and the model includes the
illness and death model as a special case. See also Beck and Chiang (1981) [12].
In many applications, modeling time-dependent transition rates is needed. Ef-
fort aiming at developing time-dependent Markov model includes a procedure to par-
tition the observation period [0, T ] into small time intervals [al−1, al], i = 1, 2, . . . , n,
0 = a0 < a1 < . . . < an = T . On each time interval the transition rate qij(t) is
assumed to be constant. Then qij(t) is a piecewise function defined by
qij(t) = q
l
ij, al−1 < t ≤ al, l = 1, 2, . . . , n
where the al’s are known constants. See examples in Andersen et al.(1993) [7] and
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Pérez-Ocón et al.(2001) [42]. The assumption of constant transition rates can be
checked by hypothesis testing. A likelihood ratio test can be used to check the fit of
the piecewise constant model to the constant transition rates model.
A better model could be obtained by increasing the number of intervals at the
cost of increasing number of unknown parameters (transition rates), which not only
increases the computation complexity but also requires larger sample sizes. Instead of
piece-wise constant functions, for a special Markov model, explicit solutions for age-
specific prevalence probabilities for time (age) and state dependent transition rates
were derived (Yang and Chang (1990) [51]). Depending on the choice of transition
rate functions, these prevalence probabilities can be non-monotonic, a requirement
for the model to fit the seroepidemiology surveys that exhibit declining prevalence
in older age. In Efromovich and Chu (2018) [20], transition rates are approximated
by Fourier series. The coefficients of the Fourier series are estimated by moment
estimators.
Generally, the requirement on the data is less stringent for parametric inferences
than that for nonparametric inferences. For example, one can carry out estimation
of the parameter λ in the exponential distribution with truncated data observed over
the time interval [0, T ] for a finite T . Once an estimator λ̂ is obtained, an estimated
survival function is e−λ̂t for all t ≥ 0. But one cannot obtain a non-parametric
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estimator of the survival function larger than the value of T with the truncated
data.
Since the publication of Aalen (1975,1978) [1][2], counting processes formula-
tion of the data and models has become one of the fundamental methods for lifetime
analysis. We can convert our observed Markov multi-state processes into counting
processes. Suppose there are n individuals in a study. Then the Markov multi-state
process ξk with state space S for the k
th individual is observed over the time inter-
val [0, τk], k = 1, 2, . . . , n. This is equivalent to recording ξk(0) and the following
counting processes:
Nkij(t) = number of direct transitions from i→ j in [0,t], i, j ∈ S, t > 0
described by the times of these transitions
0 < Y k1ij < . . . < Y
kNij(τk)
ij ,
where Y kmij is the length of time between the m
th direct transition from state i






























This is the likelihood for the general case. It can be simplified if constant or piece-
wise constant transition rates are assumed. Parametric inference is readily available
in statistics books. In situations where the maximum likelihood estimator is difficult
or even impossible to compute, M-estimators can be used. See Andersen et al.(1993)
[7] for examples.
2.4.2 Nonparametric Estimation
Aalen (1975, 1978) [1][2] introduced a nonparametric estimator Λ̂ij(t) of the
cumulative hazard function Λij(t) for right censored data as a stochastic integral
with respect to a counting process. Such a formulation permits the use of martin-
gale calculus to obtain statistical properties of the estimator. Suppose there are n
individuals under observation. Let Nij(t) be the number of individuals moving di-
rectly to state j from state i in [0, t], let Y kij be the observed sojourn time in state















Aalen and Johansen (1978) [5] proposed a nonparametric estimator in terms of
counting processes for the transition probability matrix in a finite nonhomogeneous
Markov model:




where Λ̂(t) = (Λ̂ij(t)) is the matrix of estimated transition rates and P (s, t) is the
transition probability matrix. The basic tool in their derivation is the matrix product
integral. The estimator can be thought of as the generalization of the Kaplan-Meier
estimator for general Markov multi-state models with a finite number of states. The
exact and asymptotic properties of these estimators are studied based on stochastic
integrals and martingales.
Frydman (1992) [25] proposed a nonparametric maximum likelihood procedure
for the estimation of the cumulative hazard rates in the irreversible illness-death
model. A nonparametric estimator for interval-censored data in the ilness-death
model was introduced in Frydman (1995) [26]. Both of these results were generalized




In all of the aforementioned models, each individual under study is described
using a stochastic process ξk, k = 1, 2, . . . , n with state space S = {1, 2, . . . ,m}.
The n stochastic processes are assumed to be independent and have identical dis-
tribution. In practical situations, however, the personal characteristics vary from
one individual to another and may contain valuable information which might impact
the survival time distribution. One of the most important extensions of the Kaplan-
Meier estimator was given by Cox (1972) [18], who introduced the covariate vector
(Z) associated with an individual under study in the form of a regression component
of the hazard function of that individual. As such the sample consists of n inde-
pendent but not identically distributed possibly right-censored survival times. The
Cox model facilitates multiple sample comparisons. Specifically, the Cox regression
model for the mortality model (right-censoring model) has the following hazard rate
function for an individual:
λ(t) = λ0(t) exp(−β′Z), (2.11)
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where λ0(t) is a baseline hazard rate function common to all individuals under study
(baseline hazard rate function) and the hazard rate function of an individual is
proportional to λ0(t) by a factor exp(−β′Z), where β is an unknown vector regression
coefficient.
The Cox regression model has been extensively investigated and there are many
generalizations. The proportionality assumption may fail sometimes. For example,
consider a clinical trial in which patients are randomized into either a treatment
group or control group. The event under study is the time of death of each patient.
Within the framework of Markov multi-state models, a generalized Cox regression
model can be expressed in terms of the following hazard function:
qij(t, Z) = φ(qij,0(t), β
T
ijZ), t > 0
where qij(t) is the hazard function of moving directly from state i to state j at time
t for i 6= j, φ is the link function, qij,0(t) is the baseline hazard function governing
the transition from state i and j, βij is the vector of regression coefficients, and Z
is the covariate vector representing the characteristics of an individual in the study.
The vector Z can be either time-independent or time-dependent. In the Cox model
which deals with one hazard rate function, φ(qij,0(t), β
T
ijZ) = λ0(t) exp(β
T
ijZ). The
estimation of the baseline hazard function λ0(t) and the regression parameters βij
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are commonly treated separately.
In a different approach, J.Q. Fang (1985) [21] introduced a fully parametric
model with time-dependent covariates and the baseline hazard function λ0(t) of a





where the Ys(t) are specified functions of t, and the γs are coefficients. For example,
if r = 1, Y1(t) = 1, then λ0(t) = γ1 which gives an exponential distribution. If r = 2,
Y1(t) = 1, Y2(t) = log(t), we have a Weibull distribution. One can use a r
th degree
polynomial by taking Ys(t) = t
s−1. Under Fang’s assumptions (Fang 1985 [21], p.20),
the Cox regression model can be written as
λ(t) = exp(β′X(t)) (2.13)
where X(t) is a column vector, X(t) = (x1(t), · · · , xp(t)) in which x1(t) = 1, x2(t),
· · · , xp1+1(t) are p1 time-dependent covariates, xp1+2(t) = t, · · · , xs(t) = ts−p1−1, · · · ,
xp(t) = t
p−p1−1 are quasi covariates (specified time-dependent functions) in λ0(t) and
it is assumed that p ≥ 1 + p1. This is a fully parametric model and the value p can
be estimated from the data set by using likehood ratio tests. Using Le Cam’s theory
[34], the log likehood ratios are proven to have asymptotic normal distributions
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for contiguous alternatives. Furthermore, a general Markov multi-state model with
transition rates qij(t) having a parametric form similar to (2.13) is provided in Fang
(1985) [21]. With appropriate choices of the functions Ys(t) for λ0(t), it becomes
a semi-Markov model. The model with irreversible transition paths is applied to
studying the University of California faculty promotion data.
Another approach that does not assume the proportional hazards is the additive
hazards model (Aalen 1989 [3]) given by:
qij(t, Z) = qij,0(t) + β
T
ij(t)Z, (2.14)
where the regression coefficients βij are allowed to depend on time.
Therneau and Grambsch (2013) [48] showed that if the form of the covariates
are incorrectly specified, it will lead to a diagnosis of non-proportional hazards. To
study the effects of covariates, a general proportional hazard model with arbitrary
covariate effects is proposed:
qij(t, Z) = qij,0(t) exp(f(Z)) (2.15)
where f(Z) is a smooth function. In model (2.15), the effect of the covariate vector
Z is in the form of an arbitrary smooth function f .
30
More recent works include Huang and Liu (2006) [30] which studied the para-
metric estimator of the hazard functions in the following model:
q(t, Z) = q0(t, Z) exp(ψ(β
TZ))
where ψ is an unknown smooth link function which can model the possible nonlinear-
ity of the effect of the covariates. The link function is approximated by a polynomial
spline.
When the time-dependent covariates are categorical, Cortese and Andersen
(2009) [17] suggest to incorporate the information carried by the covariate process
into the multi-state model. Each possible value that the covariate can assume over
time can be represented as a transient state.
2.5 Non-Markov Models
In numerous practical problems Markov models are not suitable. In particular
the assumption of stochastic independence in competing risks is sometimes hard to
defend. For example, in the multiple decrement model, elimination of the risk of
one type of failure might increase the risk of another type of failure (Moeschberger
(1974) [39], Prentice et al.(1978) [43]). Another example, in the illness-death model
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described in Section 2.1, Figure 2.7, if the transition rate from diseased (state 1) to
death (state 2) depends on the time of entry into the diseased state, then the process
{ξ(t) : t ≥ 0} is non-Markovian.
Strauss and Shavelle (1998) [46] extended the K-M estimator without the
Markovian assumption. Aalen et al.(2001) [4], Datta and Satten (2001) [19] studied
the performance of the estimators of state occupation probabilities derived from the
Aalen–Johansen estimators (2.10) under a non-Markovian model. More recently, us-
ing simulation, Glidden (2002) [28] obtained confidence bands for the Aalen-Johansen
estimator for the transition probabilities and showed that under a non-Markovian
condition, the Aalen-Johansen estimator may be biased. Also see Meira-Machado
et al.(2006) [36]. Meira-Machado et al.(2006) demonstrated by simulation that a
nonparametric estimator of transition probabilities which these authors introduced
outperforms the Aalen–Johansen estimator in a non-Markov situation. Putter and
Spitoni (2018) [45] proposes a relatively simple and intuitive procedure called land-
mark Aalen–Johansen (LMAJ) that will provide consistent estimators of transition
probabilities for general multi-state models.
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2.6 Recurrent Event Analysis
The Cox regression model has also been generalized for analyzing recurrent
events. For example, a commonly used one is the Andersen-Gill (AG) model (1982)
[8] which assumes that the recurrent events are independent. The intensity process
is:
λ(t) = Y (t)λ0(t) exp(X(t)β),
where Y (t) is the at-risk indicator (Y (t) = 1 if the individual is still under obser-
vation, Y (t) = 0 otherwise), λ0(t) is the baseline intensity function, X(t) is the co-
variate process and β is the coefficient vector. The difference between the AG model
and the Cox model lies in the indicator Y (t). The AG model is also applicable to
right censored data under the independent censoring assumption. In Miloslavsky et
al.(2004) [38], an estimator that accounts for dependent censoring is introduced to
improve the AG model.
The Prentice-Williams-Peterson (PWP) model [44] is similar to the AG model,
but for each recurrent event a separate intensity function is modeled:
λj(t) = Yj(t)λ0j(t) exp(X(t)βj), j = 1, 2, . . . , k.
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It can be seen as a stratified AG model. In the PWP model, the at-risk indicator
for the jth event Yj(t) is zero until the (j − 1)st event and only then becomes one.
When the jth event occurs it becomes zero again.
More recently, multi-state models have been extended for recurrent events, e.g.,
Andersen and Keiding (2002) [9]. For example, Figure 2.11 shows a multi-state model
for recurrent events. The intensities in the model can be estimated using approaches
discussed in Section 2.4.
no events first event second event . . .absorbing state
λ01(t) λ12(t) λ23(t)
Figure 2.11: Multi-state model for recurrent events.
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Chapter 3: Irreversible Markov Multi-state Model
3.1 Introduction
Our ultimate goal is to estimate the survival function. Section 3.2 gives a mo-
tivating example of the progression of patients with Aplastic Anemia (AA). Section
3.3 constructs a 4-state irreversible Markov model ξo using competing risks. Sec-
tion 3.4 states the problems to investigate where the survival function is written in
terms of a transition probability of ξo. Section 3.5 gives nonparametric estimators
of the cumulative hazard functions and an estimator of the net survival function
is obtained in Section 3.5.3. Section 3.6 deals with the case when the observation
period is a finite time interval. Section 3.7 shows the asymptotic properties of the
estimators. Section 3.8 applies the model to a real data set collected in the clinical
trial on patients with AA.
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3.2 A Motivating Example
We use a Markov model to describe the progression of a patient with Aplas-
tic Anemia (AA) with data from a clinical trial. Aplastic Anemia (AA) is a form
of bone marrow failure where the bone marrow does not produce new blood cells,
leaving the patient susceptible to bleeding and infection. Possible treatments include
blood transfusion, bone marrow transplant and medical therapy. In the clinical trial,
for patients with severe AA, treatment with immunosuppressants therapy (IST) or
a bone marrow transplant is necessary. The IST treatment involves a drug that sup-
presses the activity of immune cells which damage the bone marrow. The treatment
helps the bone marrow to recover and generate new blood cells. Patients younger
than 40 years old with a blood-matched sibling who can donate bone marrow are
usually treated by a bone marrow transplant, while patients over 40 or without a
blood-matched sibling donor are usually treated by drug therapy.
Upon the completion of the first IST, a patient is considered to be in remission.
A recovered patient may also relapse. The follow up of each patient begins immedi-
ately after the first IST until death or loss to followup. Dr. Wu of NIH, one of the
authors of Sloand et al.(2008) [47] brought this research problem to our attention
and we gratefully acknowledge the discussion with Dr. Wu. For each patient in the
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clinical trial, the times at which the events of interest occurred were recorded. The
events of interest include: the times of first IST, relapse, death and loss to followup.
For example, after the first IST, if a patient relapses and then dies, we record his/her
data as follows: date of IST, date of relapse, date of death; if a patient is lost to fol-
lowup directly after the treatment, then the observations were: date of IST, data of
last count. The data structure will be described in details in Section 3.4. In Section
3.3 through Section 3.5, we assume that the censoring time is a random variable with
support [0,∞]. However in reality, clinical trials usually terminate at a prespecified
non-negative finite time, say T , which makes the support of the censoring time vari-
able on a finite time interval [0, T ]. This case will be discussed in Section 3.6. The
comparison of the model with T =∞ and the model with T <∞ will also be made
in Section 3.6 and Section 4.2.4.
3.3 Irreversible Markov Model
Applying the F-N procedure, we construct a four-state Markov process ξo =
{ξo(t) : t ≥ 0} for the AA example described in Section 3.2, where ξo(t) represents
the status of a patient at time t, and t = 0 corresponds to the time the patient
immediately after the first IST. Throughout this chapter we assume in the model
that a patient who has relapsed will not receive a second IST. So the Markov model
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is irreversible. In the Chapter 5 we study a reversible Markov model in which a
relapsed patient may receive a second IST. The four possible states are S0, S1, S2
and S3 where:
S0: a patient is in remission immediately after first IST
S1: a patient relapses after the first remission
S2: a patient has died
S3: a patient is lost to followup
In terms of Markov processes, S2 and S3 are absorbing states, S0 and S1 are transient
states. Possible transitions in the process {ξo(t), t ≥ 0} are described schematically
in Figure 3.1. Note that this is the same model as illustrated in Figure 3.1.
S0 S1
S2 S3
Figure 3.1: Possible transition paths of a patient during the clinical trial.
A patient will take one and only one of the following four mutually exclusive
transition paths during the clinical trial:
(1) S0 → S1 → S2
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(2) S0 → S1 → S3
(3) S0 → S2
(4) S0 → S3
Patients on transition path (2) and (4) are lost to followup and thus the correspond-
ing data is right-censored. The exact time at which a transition occurs and the state
where a transition takes place are recorded. For notational convenience and consis-
tency with symbols used in Markov model, we shall denote Si by i, for i = 0, 1, 2, 3.
The transition probabilities for the Markov process are defined as
P oij(s, t) = P (ξ
o(t) = j | ξ0(s) = i), 0 ≤ s < t, i, j = 0, 1, 2, 3, (3.1)
where P oij(s, t) is the probability that a patient will be in state j at time t given that
the patient is in state i at time s. Throughout this chapter, the initial state ξo(0) is
assumed to be 0. It is assumed that the transition rates qij(t) are well-defined as
qij(t) = lim
h→0
P (ξo(t+ h) = j | ξo(t) = i)
h




qij(t), t > 0, i = 0, 1, 2, 3. (3.3)
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We assume that all qij(t)
′s are continuous in t and
∫ ∞
0
qij(u)du =∞, i 6= j, i, j = 0, 1, 2, 3. (3.4)
Constructing the Markov model from the sample paths as follows. This will be
used in simulating the Markov processes in Chapter 4.
After the initial IST, over time a patient may either die, relapse or be lost to
followup. For j = 1, 2, 3, let Y0j be the sojourn time of a patient who starts from
state 0 and stays in state 0 for the duration of Y0j before moving directly to state
j. In terms of the Markov model, Y01, Y02 and Y03 are nonnegative independent
random variables that represent time to relapse, time to death and time to loss to
followup (from the IST). For j = 1, 2, 3, let F0j(t), S0j(t) and q0j(t) be the cumulative
distribution function (CDF), the survival function and the hazard function of Y0j,
respectively. The hazard functions q0j(t) are given in (3.2). Death, relapse and loss to
followup are considered as competing risks with hazard rate q0j(t), j = 1, 2, 3. Under
the competing risks model, when a transition (an event) is observed, it means that
the time of the event occurrence is the minimum of Y01, Y02 and Y03. The observable
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quantities are a pair of random variables (Y0, δ0) defined by
Y0 = min(Y01, Y02, Y03),
{δ0 = j} = {Y0j = min(Y01, Y02, Y03)}, j = 1, 2, 3. (3.5)
The random variable Y0 is the length of time that the process ξ
o stays in state 0
before leaving 0 and δ0 = j indicates ξ
o moves directly from state 0 to state j for
j = 1, 2, 3. Then the survival function of Y0 is
S0(t) = P (Y0 > t)
= P (min(Y01, Y02, Y03) > t)
= S01(t)S02(t)S03(t), t ≥ 0 (3.6)
and
P (δ0 = j) = P (Y0j = min(Y01, Y02, Y03))




S0(u)q0j(u)du, j = 1, 2, 3. (3.7)
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The joint distribution of Y0 and δ0 is:




S0(u)q0j(u)du, t ≥ 0, j = 1, 2, 3. (3.8)
For convenience in simulation, we introduce random variables Y c0j, j = 1, 2, 3.
The distribution function of Y c0j is:
F c0j(t) = P (Y
c
0j ≤ t)
= P (Y0 ≤ t | δ0 = j)
=
G0(t, j)







S0(u)q0j(u)du, t ≥ 0, j = 1, 2, 3. (3.9)
Equation (3.9) shows that the cdf of Y c0j is the conditional cdf of Y0 given δ0 = j.
The differences between the random variables Y c0j and Y0j are as follows. A patient
in state 0 will move directly to either state 1 or 2 or 3, and his/her sojourn time
Y0 in state 0 is min(Y01, Y02, Y03). The observations are Y0 and δ0. However, for the
purpose of simulation, we find it convenient to use δ0 and the conditional distribution
of Y0 given δ0. Recall that Y
c
0j is the observed sojourn time in state 0 given that the
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patient will move to state j. The CDF of Y0 and Y
c
0j’s are related by the following
formula:












F c0j(t)P (δ0 = j), t ≥ 0, j = 1, 2, 3. (3.10)
Once a patient enters state 1, the possible next state to enter is either state 2
or state 3. By the same token, we define the following random variables for j = 2, 3:
Y1j: The sojourn time in state 1 before moving directly to state j,
Y1: The sojourn time in state 1 before moving to the next state,
δ1: The indicator random variable, δ1 = j indicates that the patient enters
state j.
Y c1j: The sojourn time in state 1 conditioned on the patient will enter state j
directly from state 1.
Let F1j(t), S1j(t) and q1j(t) be the cdf, survival function and the hazard rate
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function of Y1j, respectively, where q1j(t) is defined in (3.2), j = 2, 3. We then have
S1(t) = P (Y1 > t)
= S12(t)S13(t), t ≥ 0, (3.11)







the cdf of Y c1j is









S1(u)q1j(u)du, t ≥ 0, j = 2, 3, (3.13)
and the joint distribution of (Y1, δ1) is:




S1(u)q1j(u)du, t ≥ 0, j = 2, 3. (3.14)
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3.4 Problems to Investigate and Data Structure
Problems : We are interested in estimating the survival function of an AA
patient in the clinical trial described in Section 3.2. In our model (Figure 3.1), the
survival function computed from the process {ξo(t) : t ≥ 0} is:
So(t) = P (Xo > t | ξo(0) = 0)
= 1− P (ξo(t) = 2|ξo(0) = 0)
= 1− P o02(0, t),
where Xo denotes the survival time of a patient in the ξo model. Recall that the
Fix and Neyman procedure of identifying the (net) survival function S involves two
Markov processes, ξo and ξ (Section 2.2), where ξ = {ξ(t) : t ≥ 0} is a 3-state
Markov process ({S0, S1, S2}) with the same transition rates q01, q02, q12 as in ξo.
To compute S requires the computation of P02(0, t), from which the net survival
function of a patient is:
S(t) = P (X > t | ξ(0) = 0)
= 1− P02(0, t).
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For any Markov model considered in this thesis, given the infinitesimal matrix Q, we







Pil(s, t)qlj(t) + Pij(s, t)qjj(t), 0 ≤ s < t, i, j = 0, 1, 2, (3.15)
with initial conditions

Pii(0, 0) = 1,
lim
s→t
Pij(s, t) = 1, if i = j,
lim
s→t
Pij(s, t) = 0, if i 6= j.
(3.16)
If all of the transition rates are constant in t, the solutions for the transition proba-
bilities are known. For time dependent qij(t), Feller (1940) [22] proved the existence
and uniqueness of the solutions. However, except in some special cases such as an
irreversible Markov process, there are no closed-form solutions. We rely on numerical
methods to obtain the solutions, in particular for the survival function.
Data: Following the AA example (Section 3.2), suppose there are n patients
in the clinical trial. The changes over time of the kth patient, for k = 1, . . . , n are
assumed to be n i.i.d. Markov processes ξok = {ξok(t), t ≥ 0}. For any patient, we
observe his/her sojourn time in state 0 or 1 before moving directly to the next state.
Our observed data are as follows:
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(1) {(Y0,k, δ0,k) | k ∈ 1, . . . , n, δ0,k = 1},
(2) {(Y0,k, δ0,k) | k ∈ 1, . . . , n, δ0,k = 2},
(3) {(Y0,k, δ0,k) | k ∈ 1, . . . , n, δ0,k = 3},
(4) {(Y1,k, δ1,k) | k ∈ 1, . . . , N01, δ1,k = 2},
(5) {(Y1,k, δ1,k) | k ∈ 1, . . . , N01, δ1,k = 3}.
Note that, if for j = 1, 2, 3 we let N0j(t) be the number of patients who started
from state 0 and moved directly to state j in [0, t], t > 0, for j = 2, 3 let N1j(t) be the
number of patients who landed in state 1 and moved to state j in [0, t], t > 0. Then
for any t > 0 we should haveN01(t)+N02(t)+N03(t) = n andN12(t)+N13(t) = N01(t).
Let N0(t) = (N01(t), N02(t), N03(t)). Then given t = y0, N0(y0) follows a multinomial
distribution with parameters n and p0(y0) = (p01(y0), p02(y0), p03(y0)) where
p0j(y0) = lim
dt→0
P (Y0j = min(Y01, Y02, Y03) | Y0 ∈ [y0, y0 + dt))
= lim
dt→0
P (Y0j = min(Y01, Y02, Y03), Y0 ∈ [y0, y0 + dt))






















The probabilities p0j are functions of time, evaluated at y0, which give the proba-
bility of event j happening at time y0, j = 1, 2, 3. Similarly given t = y1, N1(y1) =











Following Section 3.3, under model {ξo(t) : t ≥ 0}, we construct nonparamet-
ric estimators of the cumulative hazard functions, transition probabilities and the
survival function respectively.
48
3.5.1 Estimators of Cumulative Hazard Functions
The denominator in (3.9) is the probability




S0(u)q0j(u)du, j = 1, 2, 3. (3.20)






















, t ≥ 0, j = 1, 2, 3. (3.23)
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Note that in (3.23), the unknown constant α0j in the numerator and denominator
is cancelled. For j = 1, 2, 3, a nonparametric estimation of q0j(t) can be performed
by the estimation of G0(t, j) and S0(t) with the data {Y0,k, δ0,k, k = 1, 2, . . . , n} and
{Y1,k, δ1,k, k = 1, 2, . . . , N01} (see Section 3.4).
Let t0j = max
k=1,2,...,n
{Y0,k | δ0,j = j} be the largest uncensored observation of
Y0j, j = 1, 2, 3. Let t1j = max
k=1,2,...,n
{Y1,k | δ1,j = j} be the largest uncensored ob-
servation for Y1j, j = 2, 3. Let t0 = max(t01, t02, t03), t1 = max(t12, t13). Then the












I{Y0,k > t}, t ∈ [0, t0]. (3.25)




, t ∈ [0, t0j], j = 1, 2, 3. (3.26)
In (3.26), Ĝ0(t, j) is a step function. Therefore
dĜ0(t, j) = Ĝ0(t, j)− Ĝ0(t−, j). (3.27)
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Integrating both sides of (3.26), we obtain an estimator of the cumulative hazard













I(Y0,k ≤ t, δ0,k = j)∑n
m=1 I(Y0,m > Y0,k)
, t ∈ [0, t0j], j = 1, 2, 3. (3.28)














I(Y1,k ≤ t, δ1,k = j)∑N01
m=1 I(Y1,m > Y1,k)
, t ∈ [0, t1j], j = 2, 3. (3.30)
3.5.2 Estimators of Transition Probabilities
Corresponding to the transition paths depicted in Figure 3.1, the infinitesimal
matrix of our Markov model is Qo(t), t > 0:
Qo(t) =

q00(t) q01(t) q02(t) q03(t)
0 q11(t) q12(t) q13(t)
0 0 0 0
0 0 0 0
 (3.31)
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Given Qo(t), only seven transition probabilities are nonzero. Applying the Kol-




= P o00(0, t)q00(t),
dP o01(0, t)
dt















= P o11(0, t)q11(t),
dP o12(0, t)
dt
= P o11(0, t)q12(t),
dP o13(0, t)
dt
= P o11(0, t)q13(t),
with initial conditions (3.16). The solutions are:

















P o00(u)q01(u) du, (3.33)

























P o12(0, t) =
∫ t
0
P o11(0, u)q12(u) du, (3.37)
P o13(0, t) =
∫ t
0
P o11(0, u)q13(u) du. (3.38)
Estimators of the transition probabilities P oij(0, t) can be obtained by plugging (3.26)
and (3.29) into (3.32), . . ., (3.38).
3.5.3 Estimator of Net Survival Function
The infinitesimal matrix of the 3-state Markov process ξ is
Q∗(t) =




q∗00(t) = −q01(t)− q02(t),
q∗11(t) = −q12(t).
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The transition probabilities Pij(0, t) in ξ can be solved using Kolmogorov forward
equations (3.15). The solutions are:






















P00(0, u)q02(u) + P01(0, u)q12(u)
]
du. (3.42)
Actually, instead of solving the Kolmogorov equations for the 3-state ξ, we can easily
obtain the solutions P00(0, t) in (3.40), by setting q03(t) = 0 in q00(t) in the solution
P o00(0, t) in (3.32). Similarly, P01(0, t) in (3.41) is obtained by setting q13(t) = 0 in
q11(t) in the solution P
o
01(0, t) in (3.33), and P02(0, t) in (3.42) is obtained by setting
q03(t) = q13(t) = 0 in the solution P
o
02(0, t) in (3.34).
For estimation of P02(0, t), we need estimates of q01(t), q02(t) and q12(t). We
can use q̂01(t), q̂02(t) and q̂12(t) in (3.26) and (3.29). An estimator of P02(0, t) in
ξ can be obtained by plugging (3.26) and (3.29) into (3.40) . . . (3.42). Denote the
obtained estimator as P̂02(0, t). Then an estimator of the net survival function of a
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patient is





P̂00(0, u)q̂02(u) + P̂01(0, u)q̂12(u)
]
du. (3.43)
3.6 Clinical Trial Terminating at a Finite Time T
In Sections 3.2 through 3.5, the estimation is carried out under the assumption
that the clinical trial terminates when all the patients are dead or lost to followup
where there is no termination date for the clinical trial. In this section, we will
discuss estimation of Λij(0, t), Pij(0, t) and S(t) for a clinical trial that terminates at
a prespecified finite time T .
In (3.5), Y0 = min(Y01, Y02, Y03), where Y03 is the sojourn time in state 0 before
being lost to followup and the support of Y03 is assumed to be [0,∞]. In this section,
the clinical trial terminates at time T , therefore we assume that 0 < Y03 ≤ T .
Then our observations are limited to [0, T ]. Similar to Section 3.5.1, for each patient
starting from state 0, we observe a pair of random variables (Y0, δ0), where:
Y0 = min(Y01, Y02, Y03), Y0 ∈ (0, T ],
{δ0 = j} = {Y0 = Y0j}, j = 1, 2, 3.
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The survival function of Y0 is:
S0(t) =
{
S01(t)S02(t)S03(t), 0 < t ≤ T
0, t > T.
The distribution function of δ0 is:
P (δ0 = j) =
∫ T
0
S0(u)q0j(u)du, j = 1, 2, 3,
The joint distribution of Y0 and δ0 is:




S0(u)q0j(u)du, 0 < t ≤ T, j = 1, 2, 3. (3.44)
The estimators of the cumulative hazard functions Λ0j(0, t), j = 1, 2, 3 can be de-





I(Y0,k ≤ t, δ0,k = j)∑n
m=1 I(Y0,m > Y0,k)
, t ∈ [0, t0j], j = 1, 2, 3. (3.45)
For patients moved to state 1 before the end of the clinical trial, i.e., given
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Y01 < T , we observe another pair of random variables (Y1, δ1), where:
Y1 = min(Y12, Y13, T − Y01),
{δ1 = 2} = {Y1 = Y12},
{δ1 = 3} = {Y1 = min(Y13, T − Y01)}.
If we define Y ∗13 = min(Y13, T − Y01), then Y1 = min(Y12, Y ∗13). The survival function
of Y ∗13 is:
S∗13(t) = P (Y
∗
13 > t)
= P (Y13 > t, T − Y01 > t | Y01 < T )
= S13(t)F01(T − t)/F01(T ), 0 < t ≤ T.
The survival function of Y1 is:
S1(t) = P (Y1 > t)





13(t), 0 < t ≤ T.
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The joint distribution of (Y1, δ1) is:




S1(u)q12(u)du, 0 < t ≤ T,






13(u)du, 0 < t ≤ T,









, 0 < t ≤ T.




I(Y1,k ≤ t, δ1,k = j)∑N01
m=1 I(Y1,m > Y1,k)
, t ∈ [0, t1j], j = 2, 3. (3.46)
We see that the estimators (3.45) and (3.46) are the same as (3.28) and (3.30)
on [0, T ]. Let (y0,k, δ0,k), k = 1, 2, . . . , n, be the observed data when the observation
period is [0,∞). We consider two consecutive time intervals [0, T ] ∪ (T,∞). For a
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clinical trial that terminates at a finite time T , its observations in [0, T ] for patients
starting in state 0 are the same as those with observation period [0,∞) but observed
in [0, T ]. We observe exactly the same data on [0, T ] whether the observation period
is [0, T ] or [0,∞). Therefore, for j = 1, 2, 3 the estimated Λ̂0j(0, t) and σ̂20j(t) are the
same on [0, T ] when the observation periods are [0, T ] and [0,∞).
However, the observations on patients in state 1 are different when T < ∞
instead of T = ∞. The observed patients are in state 1 before the termination of
the clinical trial. Then for each of them the sojourn time in state 0 is less than T .
Suppose we observe (y1,k, δ1,k), k = 1, 2, . . . , n01 when T = ∞. When T becomes
finite, for the kth patient, the remaining observation time becomes T − y0,k given
y0,k < T . Therefore the observation on the k
th patient becomes min(y1,k, T − y0,k).
This differs from the case for T =∞. The termination of the clinical trial (T <∞)
also has an impact on the variance of Λ̂1j(0, t) because we observe fewer transitions.
When T < ∞, the variance of Λ̂1j(0, t) is larger than that when T = ∞. It can be
seen in the Figures from the simulations in Section 4.2.4.
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3.7 Asymptotic Distributions of the Estimators
3.7.1 Cumulative Hazard Functions
Estimators of the cumulative hazard functions Λ0j(0, t) and Λ1j(0, t) are given
in (3.28) and (3.30) respectively. The estimators are derived from a Markov multi-
state model. We can also formulate the estimators using counting processes. Con-
sider a multivariate counting process N0(t) = (N01(t), N02(t), N03(t)), where N0j(t) =∑n
k=1 I[Y0,k ≤ t, δ0,k = j], j = 1, 2, 3. Assume that the intensity process λ0(t) =
(λ01(t), λ02(t), λ03(t)) satisfies the multiplicative model λ0j(t) = q0j(t)H0(t), where
H0(t) =
∑n





−1dN0j(u), t ∈ [0, t0j], j = 1, 2, 3. (3.47)
Similarly we can also formulate Λ̂1j(0, t) in terms of counting processes. This is
known as the Nelson-Aalen estimator.
The properties of the Nelson-Aalen estimator have been studied by Aalen
(1975, 1978b) [1][2] and Andersen et al.(1993) [7]. In this section, we will derive the
bias, estimated variance, uniform consistency and asymptotic normality of Λ̂0j(0, t)
and Λ̂1j(0, t) using results from Aalen (1978b). See also Section 4.1 of Andersen et
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al.(1993). The results are stated using Markov multi-state model notations.
(1) Bias








q1j(u)P (Ŝ1(u) > 0)du, t ∈ [0, t1j], j = 2, 3.
If for all t ∈ [0, t0j], Ŝ0(t) > 0 and Ŝ1(t) > 0, then Λ̂0j(0, t) and Λ̂1j(0, t) are
unbiased estimators of Λ0j(0, t) and Λ1j(0, t) on [0, t0j] and [0, t1j] respectively.
Since the nonparametric estimator Λ̂0j(0, t) is identifiable up to the last uncen-
sored observation, Ŝ0(t) is positive for all t ∈ [0, t0j]. Therefore, Λ̂0j(0, t) is an
unbiased estimator of Λ0j(0, t) on [0, t0j]. Similarly, we conclude that Λ̂1j(0, t)
is an unbiased estimator of Λ1j(0, t) on [0, t1j].
(2) Variance










−2dĜ1(u, j), t ∈ [0, t1j], j = 2, 3. (3.49)
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(3) Consistency
The following theorem (Theorem 4.1.1 in Andersen et al.(1993)) shows that
Λ̂0j(0, t), j = 1, 2, 3, are uniformly consistent on compact intervals.




















| Λ̂0j(0, s)− Λ0j(0, s) |
P−→ 0. (3.52)
Condition (3.51) is obvious since Ŝ0 is always positive on [0, t0,j] for j = 1, 2, 3.
We now check condition (3.50). The empirical survival function Ŝ0 converges





Then for a given ε0 > 0 such that S0(s) − ε0 > 0 for all s ∈ [0, t], there exists
N > 0 such that when n ≥ N , 0 < S0(s) − ε0 ≤ Ŝ0(s) ≤ S0(s) + ε0 for all
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Since S0(t)− ε0 > 0 and q0j is integrable on [0, t], the RHS of (3.53) converges
to 0 pointwise. Then condition (3.50) follows directly. The uniform consistency
of Λ̂1j(0, t), j = 2, 3 can be derived in the same way.
(4) Asymptotic Distribution
The asymptotic distribution of Λ̂0j(0, t) for j = 1, 2, 3 on [0, t0j] is stated in The-
orem 4.1.2 in Andersen et al.(1993). Define Λ̂0(0, t) = (Λ̂01(0, t), Λ̂02(0, t), Λ̂03(0, t)),
and define Λ0(0, t) in a similar manner.
Theorem 3.7.2. Let t ∈ [0, t0j] and assume that q0j/S0 is integrable over







du, j = 1, 2, 3, (3.54)
and assume that







P−→ σ20j(t) as n→∞. (3.55)
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P−→ 0 as n→∞. (3.56)






1− I[Ŝ0(u) > 0]
)
q0j(u)du




D−→ U = (U01, U02, U03) as n→∞ (3.58)
on D[0, t01]×D[0, t02]×D[0, t03], where U01, U02, U03 are independent Gaussian
martingales with U0j(0) = 0 and cov(U0j(s1), U0j(s2)) = σ
2
0j(s1 ∧ s2), Also, for
j = 1, 2, 3,
sup
t∈[0,t0j ]
∣∣nσ̂20j(t)− σ20j(t)∣∣ P−→ 0 as n→∞, (3.59)
where σ̂20j(s) is defined by equation (3.48).
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In Theorem 3.7.2, conditions A to C are satisfied if inft∈[0,t0j ] S0(t) > 0 and
sup
t∈[0,t0j ]
∣∣∣Ŝ0(t)− S0(t)∣∣∣ P−→ 0 as n→∞, (3.60)
assuming that Λ0j(0, t) <∞ for all t ∈ [0, t0j], j = 1, 2, 3. Since Ŝ0 is the empir-
ical survival function, condition (3.60) is obviously satisfied. The asymptotic
distribution of Λ̂1j(0, t) can be derived in the same way.
3.7.2 Net Survival Function
The estimated Ŝ(t) in (3.43) is a function of Λ̂01(0, t), Λ̂02(0, t) and Λ̂12(0, t):









































Ŝ = γ(Λ̂01, Λ̂02, Λ̂03)
= 1− γ1(Λ̂01, Λ̂02)− γ2(Λ̂01, Λ̂02, Λ̂12).
We first derive the first-order Hadamard derivatives of γ1 and γ2. Let F0, G0 and
H0 be functions from R+ to R+, Ftn = F0+tnFn, Gtn = G0+tnGn, Htn = H0+tnHn,
where Fn, Gn and Hn are any functions from R+ to R+ such that Fn → F , Gn → G,
Hn → H and tn → 0 as n→∞, then the derivative of γ1 at (F0, G0) is:
γ′1(F0,G0)(F,G) =








































exp(−F0 −G0)dG as n→∞.
(3.61)
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To derive γ′2, notice that if we let γ3(S,H) =
∫ t
0
exp(−H)SdH, γ4(F,G,H) =∫ t
0
exp(H − F − G)dF , γ5(F,G,H) = (γ4(F,G,H), H), then γ2 = γ3 ◦ γ5. By the





We can derive γ′3(S0,H0)(S,H) and γ
′
5(F0,G0,H0)
(F,G,H) similarly as follows:
γ′3(S0,H0)(S,H) =

















































exp(Htn − Ftn −Gtn)dFtn −
∫ t
0



































exp(H0 − F0 −G0)dF as n→∞. (3.63)
Then γ′5(F0,G0,H0)(F,G,H) = (γ
′
4(F0,G0,H0)















































exp(H0 − F0 −G0)dF.












































−(F ∗ +G∗) exp(−F0 −G0 − tn(F ∗ +G∗))dG0 +
∫ t
0





exp(−Ftn −Gtn)− exp(−F0 −G0)
]
dGn, (3.65)
where F ∗ is between F0 and F0 + tnFn, G
∗ is between G0 and G0 + tnGn. Let tn → 0
69






γ1(Ftn , Gtn)− γ1(F0, G0)− γ′1,(F0,G0)(tnFn, tnGn)} = 0.













γ4(Ftn , Gtn , Htn)− γ4(F0, G0, H0)− γ′4,(F0,G0,H0)(tnFn, tnGn, tnHn)} = 0.




(Λ̂01, Λ̂02, Λ̂03)− (Λ01,Λ02,Λ03)
)






D−→ (U12, U13) as n→∞.

















Then the asymptotic distribution of Ŝ follows from the functional delta method (Van
















where Λ = (Λ01,Λ02,Λ12) and γ
′
Λ = −γ′1Λ - γ′2Λ with γ′Λ, γ′1Λ and γ′2Λ being the
first-order Hadamard derivatives of γ, γ1 and γ2 at Λ. By (3.66), the asymptotic
distribution of Ŝ follows.
3.8 Application to Aplastic Anemia Data
In Section 3.2, we discuss the Aplastiic Anemia data as a motivating example.
A four-state Markov process is constructed for this problem. We apply the nonpara-
metric estimators of the cumulative hazard functions ((3.28) and (3.30)), transition
probabilities and net survival function ((3.43)) to the AA data.
There are 238 patients in the clinical trial. The clinical trial lasts for about 21
years. Each patient was followed after the first IST treatment. Over time, 80 of the
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patients relapsed, 151 were lost to followup and 7 died directly after the first IST.
These refer to direct transitions from state 0 to state 1, state 2 and state 3. Further,
of the 80 relapsed patients, 23 died and 57 were lost to followup. The number of
patients on each transition path is illustrated in Figure 3.2. For each patient, the
data include the times when transitions happened and hence we can calculate the
sojourn times between any two direct transitions. Our purpose is to estimate the
survival function of the patients.
S0: Treatment S1: Relapse






Figure 3.2: Transition paths of AA patients
We plot the estimated crude transition probabilities P̂ oij(0, t) in Figure 3.3.
We compare each P̂ oij(0, t) with the corresponding empirical transition probability
P oij,n(0, t) which is defined as
P oij,n(0, t) =
# {patients in state i at time 0 and in state j at time t}
# {patients in state i at time 0}
.
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Figure 3.3: Comparison of P̂ oij(0, t) and P
o
ij,n(0, t). The black line is P
o
ij,n(0, t), the
red line is P̂ oij(0, t).
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Figure 3.4: Comparison of Ŝ(t) = 1 − P̂02(0, t) and the Kaplan-Meier estimator.




The graph of the estimated net survival function Ŝ(t) = 1 − P̂02(0, t) and the
Kaplan-Meier estimator is shown in Figure 3.4.
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Chapter 4: Simulation for Irreversible Markov Model
Simulations are often used to study distributional properties of estimators both
for large samples and small samples, especially when the finite-sample distribution is
hard to derive. Also, accuracy of the estimation results obtained from the simulation
can be verified by the theoretical model that are used for the simulation. In this
section, simulations are conducted to check the goodness of fit of the estimators of
cumulative hazard functions.
Since our clinical trial data are modeled by Markov processes, our basic sample
consists of n mutually independent Markov processes {ξok(t), t ≥ 0}, k = 1, 2, . . . , n.
We will simulate {ξo(t), t ≥ 0} for each of the n patients.
4.1 Simulation Procedure
In Section 3.3, we use Y0 (see (3.5)) to represent the sojourn time of a patient
in the initial state 0 before he/she moves to to the next state. It is assumed that Y0 is
a random variable determined by 3 other mutually independent nonnegative random
75
variables Y01, Y02 and Y03 as Y0 = min(Y01, Y02, Y03). After staying in state 0 for Y0
amount of time, the patient can enter either state 1, 2 or 3 according to the following
chance mechanism. Of the three sojourn times Y0j, j = 1, 2, 3, we only observe the
minimum. As far as simulation goes, there are two different but equivalent ways of
simulating the Markov process.
The first method: starting from state 0, we generate three random variables
Y01 = y01, Y02 = y02 and Y03 = y03, denote the observed minimum of y01, y02 and
y03 as y0 and record the index δ0 of the minimum random variable, δ0 = 1, 2, 3. If
y02 or y03 is the minimum, i.e., δ0 = 2 or 3, then the next transition is to state 2
or 3 accordingly. Since both state 2 and state 3 are absorbing states, we are done
with this transition path of this patient. If y01 is the minimum, i.e., δ0 = 1, then
starting from state 1 (at time y01), we generate two random variables Y12 = y12 and
Y13 = y13, in which y12 is the sojourn time in state 1 before moving to state 2, and
y13 is the sojourn time in state 1 before moving to state 3. Similar to the direct
transition from the initial state 0, we record the minimum Y1 and the index δ1 of
the minimum random variable for the next transition event. The simulated data
are pairs of random variables: (Y0, δ0) and (Y1, δ1), where Yj and δj are dependent
random variables.
The second method is to use the multinomial distributions discussed in (3.17)
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∼ (3.19) in Section 3.5.1. To begin with, we generate a sojourn time Y0 = y0 directly
from the distribution F0(t) = 1 − S0(t) (see (3.6)) using inverse transformation
sampling, where Y0 is the time spent in state 0 before the patient entering the next
state. To be clear, consider an example using the Weibull distribution. Assume that
Y0 follows the Weibull distribution with CDF F0(t) = 1− exp(−(t/η)γ). Simulate a
Unif [0, 1] random variable x0, let y0 = F
−1
0 (x0) where F
−1
0 is the inverse function of
F0. Then y0 is an observed random sample from Weibull(γ, η). After we simulate
the sojourn time in state 0, we need to decide which state the patient has entered or
we say which event has occurred. The index of the next event follows a multinomial
distribution. The possible values of a multinomial trial are 1, 2 and 3 with probability
p01, p02 and p03 respectively. The probabilities p0j, j = 1, 2, 3 are defined in (3.17).
If the next event is to enter state 2 or 3, we stop the simulation. Because they
are absorbing states. Otherwise, if the next event is entering state 1, we generate
sojourn time Y1 = y1. Then there are two choices: either state 2 or state 3. Thus
instead of a trinomial distribution we have a Bernoulli distribution of choices where
the probability of choosing state 2 is p12(y1) and of choosing state 3 is p13(y1) =
1− p12(y1). The number chosen is the index of the next occurring event.
It is easy to show that the two methods described above are mathematically
equivalent. First we note that the distributions of δ0 and δ1, are the same for both
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methods. The distribution of δ0 is trinomial. In method one, we have:





= α0j, j = 1, 2, 3. (4.1)
In method two, the distribution of δ0 is:










= α0j, j = 1, 2, 3. (4.2)
Second, the joint distributions of (Y0, δ0) in each of the two methods are also the
same (see (3.8)). Therefore, the two simulation methods are mathematically equiv-
alent. We can choose either method to simulate the transition paths. The following
simulations are carried out using method two as it has a more natural interpretation
in terms of the clinical trial.
The simulation procedure is as follows:
(1) Generate Y0 = y0 from distribution function F0(t) = P (Y0 ≤ t) = 1 − S0(t)
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(see (3.6)) using inverse transform sampling.




(3) If δ0 = 2 or δ0 = 3, stop. The observed transition path is 0→ 2 or 0→ 3, and
the observed time of transition is y0. Otherwise continue to step (4).
(4) If δ0 = 1, generate Y1 = y1 from distribution function F1(t) = P (Y1 ≤ t) =
1− S1(t) (see (3.11)).




(6) If δ1 = 2 or δ1 = 3, the observed transition path is 0 → 1 → 2 or 0 → 1 → 3,
the observed times of transition are y0 and y1.
Repeat the procedure (1) through (6) for each of the n patients to obtain a sample
of n independent Markov process, where n is the prespecified sample size. In the
next section, simulations are conducted under the following assumptions:
(a) Y01 ∼ gamma(2.6, 0.8), Y02 ∼ gamma(4, 1) where in gamma(α, β), α is the
shape parameter and β is the rate parameter.
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(b) Y03 ∼ Weibull(1.5, 5), Y12 ∼ Weibull(1.5, 4), Y13 ∼ Weibull(1.2, 6) where in
Weibull(γ, η), γ is the shape parameter and η is the scale parameter.
(c) Yij, i, j = 0, 1, 2, 3 are independent random variables.
The parameters used in the gamma and Weibull distributions are selected so that the
mean of each Yij is similar to the corresponding mean calculated from the Aplastic
Anemia data set.
4.2 Simulation Results
Estimation of the cumulative hazard functions, the transition probabilities and
the net survival function are carried out with the simulated data. Our simulated
data are as follows:
(1)
{
























4.2.1 Estimators of Cumulative Hazard Functions with Simulated
Data
Estimators of the cumulative hazard functions Λ0j(0, t) and Λ1j(0, t) can be




I(y0,k ≤ t, δ0,k = j)∑n
m=1 I(y0,m > y0,k)




I(y1,k ≤ t, δ1,k = j)∑n01
m=1 I(y1,m > y1,k)
, t ∈ [0, t1j], j = 2, 3. (4.4)
We only display the graphs of Λ01(0, t) and Λ03(0, t) and their estimates in
Figure 4.1 and Figure 4.2, where Λ01(0, t) is the cumulative hazard function of
gamma(2.6, 0.8) and Λ03(0, t) is the cumulative function of Weibull(1.5, 5). On each
figure, we display the graphs corresponding to sample size n = 200, n = 500 and
n = 1000. The black line represents Λij(0, t), the red line represents Λ̂ij(0, t), the
blue dashed lines represents the 95% confidence intervals of Λ̂ij(0, t), the green dot-
dashed line indicates the largest uncensored survival time in the sample, that is
max
k=1,2,...,nij
{yi,k | δi,k = j}. Each Λij(0, t) is only identifiable up to the largest un-
censored survival time. By comparing Λ̂ij(0, t) with Λij(0, t), we see that in general
as the sample size increases, the deviation of Λ̂ij(0, t) from Λij(0, t) decreases. The
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I[Y0,k ≤ t, δ0,k = j][∑n
m=1 I[Y0,m ≥ Y0,k]




I[Y1,k ≤ t, δ1,k = j][∑n01
m=1 I[Y1,m ≥ Y1,k]
]2 , t ∈ [0, t1j], j = 2, 3. (4.6)
The estimated variances σ̂20j(t) and σ̂
2
1j(t) are functions of the sample size n. For
any t ∈ [0, tij], σ̂2ij(t) = O(1/n). Therefore the variance decreases as the sample size
grows. As a result, the width of the confidence interval decreases as the sample size
grows.
Figure 4.1 and 4.2 are generated from a single simulation. Now we repeat the
simulation for 1000 times and calculate the mean of the estimated cumulative hazard
functions at each time point. We plot the mean computed from 1000 simulations. We
only display the graph of Λ01 for n = 200 and n = 500 in Figure 4.3 to demonstrate
the difference between a single simulation and repeated simulations. Notice that in
Figure 4.3, the red line is smooth and almost coincides with the black line. Because
when we repeat the simulation for 1000 times, at each time point t, by the Law
of Large Numbers the mean of Λ̂01(0, t) converges in probability to Λ01(0, t) as the
sample size approaches infinity.
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, t > 0, α = 2.6, β = 0.8


























(a) n = 200


















(b) n = 500
























(c) n = 1000
Figure 4.1: Comparison of Λ̂01(0, t) and Λ01(0, t) for n = 200, 500, 1000, where the black line
is Λ01(0, t), the red line is Λ̂01(0, t), the blue lines are the 95% confidence interval, the green line







, t > 0, γ = 1.5, η = 5




















(a) n = 200






















(b) n = 500


























(c) n = 1000
Figure 4.2: Comparison of Λ̂03(0, t) and Λ03(0, t) for n = 200 and n = 500, where the black
line is Λ03(0, t), the red line is Λ̂03(0, t), the blue line is the 95% confidence interval, the green line
indicates the largest uncensored observation: max(y0,k|δ0,k = 3).
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, t > 0, α = 2.6, β = 0.8



















(a) n = 200















(b) n = 500
Figure 4.3: Comparison of Λ01(0, t) and the mean of Λ̂01(0, t) computed from 1000 simulations
for n = 200, 500. The black line is Λ01(0, t), the red line is the mean of Λ̂01(0, t), the blue lines are
the 95% confidence interval.
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4.2.2 Estimators of Crude Transition Probabilities with Simulated
Data
In Section 3.5.2, we obtained estimators of the crude transition probabilities
P oij(0, t) using Kolmogorov froward equations. Of the seven nonzero transition prob-




11(0, t) and P
o
02(0, t)
because 1−P02(0, t) is the net survival function that is a function of P00(0, t), P01(0, t)
and P11(0, t). Because the graph of P
o
11(0, t) is similar to that of P
o
00(0, t), we only




02(0, t) and their estimates in Figure 4.4
through Figure 4.6. In each figure, we display the graphs corresponding to n = 200,
n = 500 and n = 1000.
4.2.3 Estimator of Net Survival Probability with Simulated Data
We plot Ŝ(t) (see (3.43)) under our Markov model and compare it with the
Kaplan-Meier estimator for n = 200, n = 500 and n = 1000 in Figure 4.7.
Figure 4.7 shows that the Kaplan-Meier estimator of the survival probability
is higher than Ŝ(t) for all t > 0 and all three sample sizes.
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(a) n = 200















(b) n = 500















(c) n = 1000
Figure 4.4: Comparison of P̂ o00(0, t) and P
o
00(0, t) for n = 200, n = 500 and n = 1000. The black



















(a) n = 200













(b) n = 500













(c) n = 1000
Figure 4.5: Comparison of P̂ o01(0, t) and P
o
01(0, t) for n = 200, n = 500 and n = 1000. The black

















(a) n = 200













(b) n = 500















(c) n = 1000
Figure 4.6: Comparison of P̂ o02(0, t) and P
o
02(0, t) for n = 200, n = 500 and n = 1000. The black


















(a) n = 200, censoring rate = 103200














(b) n = 500, censoring rate = 227500














(c) n = 1000, censoring rate = 4891000
Figure 4.7: Comparison of Ŝ(t) = 1− P̂02(0, t) ((3.43)) and Kaplan-Meier estimator for n = 200,
n = 500 and n = 1000. The black line represents the Kaplan-Meier estimator, the red line represents
Ŝ(t).
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4.2.4 Clinical Trial Terminating at a Finite Time T
We compare the graphs of Λ̂ij(0, t), P̂
o
ij(0, t) and Ŝ(t) for T = ∞ and T < ∞
in Figure 4.8 through Figure 4.10. We use T = 5 in the simulation.
Similar to Section 4.2, we estimated the crude transition probabilities P o00(0, t),




02(0, t) and the net survival function S(t). We only display the
graph of Ŝ(t) and compare it with Kaplan-Meier estimatorfor n = 200, n = 500 and
n = 1000.
From the Figure 4.10, we can see that when T = ∞ and T = 5, the Kaplan-
Meier estimators are the same on [0, 5]. And Ŝ(t) is lower than the Kaplan-Meier
estimator for all three sample sizes both when T =∞ and T = 5. A possible reason
for this may be as follows. From Section 2.2 we know that the Kaplan-Meier model
can be described by a 3-state Markov process. The three states are: treatment (S0),
death (S1) and loss to followup (S3). It does not include a state for relapse, thus it
does not utilize all the available patients status data.
4.3 Hypothesis Testing
It can be seen from Figure 4.1 and Figure 4.2 that Λ̂01(0, t) and Λ̂03(0, t) are
close to the true cumulative hazard functions and the deviation decreases as the
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, t > 0, α = 2.6, β = 0.8



















(a) n = 200

















(b) n = 500



















(c) n = 1000
Figure 4.8: Comparison of Λ̂01(0, t) and Λ01(0, t) for n = 200, 500, 1000, where the black line
is Λ01(0, t), the red line is Λ̂01(0, t), the blue lines are the 95% confidence interval when T = ∞,
the orange lines are the 95% confidence interval when T = 5, the green line indicates the largest
uncensored observation when T = ∞, the pink line indicates the largest uncensored observation







, t > 0, γ = 1.5, η = 4



















(a) n = 200



















(b) n = 500



















(c) n = 1000
Figure 4.9: Comparison of Λ̂12(0, t) and Λ12(0, t) for n = 200, 500, 1000, where the black line
is Λ12(0, t), the red line is Λ̂12(0, t), the blue lines are the 95% confidence interval when T = ∞,
the orange lines are the 95% confidence interval when T = 5, the green line indicates the largest
uncensored observation when T = ∞, the pink line indicates the largest uncensored observation
when T = 5.
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(a) n = 200, censoring rate = 103200 when
T = ∞, censoring rate = 123200 when T = 5.














(b) n = 500, censoring rate = 227500 when
T = ∞, censoring rate = 285500 when T = 5.














(c) n = 1000, censoring rate = 4891000 when
T = ∞, censoring rate = 6081000 when T = 5.
Figure 4.10: Comparison of Ŝ(t) = 1 − P̂02(0, t) and the Kaplan-Meier estimator when T = ∞
and T = 5 for n = 200, n = 500 and n = 1000. The black solid line is the Kaplan-Meier when
T = 5, the black dashed line is the Kaplan-Meier estimator when T =∞, the red solid line is Ŝ(t)
when T = 5, the red dashed line is Ŝ(t) when T =∞.
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sample size increases. However, formal statistical hypothesis testing is still necessary
to theoretically measure the goodness of fit of our Markov model.
4.3.1 Kolmogorov-Smirnov Test
We take Y01 as an example to show the hypothesis testing procedure. We
derived an estimator Λ̂01(0, t) of Λ01(0, t). We can further derive an estimator of the
distribution function of Y01: F̂01(t) = 1 − exp(−Λ̂01(0, t)). Denote the distribution
function of Y01 in our model by F01,0 (in the simulation, we use gamma(2.6, 0.8)).
Our null and alternative hypotheses are as follows:
H0 : F01 = F01,0 vs. Ha : F01 6= F01,0
The Kolmogorov-Smirnov (K-S) test statistic measures the supreme distance
between the empirical distribution function Fn(t) of a complete sample of i.i.d ran-
dom variables and the hypothetical distribution function F0(t). The Kolmogorov-




Using Dn we would reject H0 if the computed Dn value, say dn, is larger than the
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critical value cα. However, the distribution of Dn is only known and independent of
F0 for complete samples. Various modifications of the K-S test statistic are available
in the literature for carrying out hypothesis testing of H0 vs. Ha with right censored
data. See review in Nikulin, Lemeshko, Chimitova and Tsivinskaya (2011) [41]. To
this end, Nikulin, et al.. (2011) [41] proposes a test statistic in their equation (1).







The asymptotic distribution of D∗n involves the amount of censoring in the data.
However, the asymptotic distribution of D∗n under H0 is unknown and its approxi-
mated distribution is obtained by simulation. Based on simulated distribution, the
cutoff value cα and the P-value of the modified test are determined. We adapt the
method in Nikulin et al.. (2011) [41] to simulated the distribution of D∗n.
We would reject H0 if D
∗
n is greater than the critical value cα. We simulate
5000 samples of (Y0, δ0) of a given sample size n, for n = 200, 500 and 1000. The test
statistic D∗n is calculated for each sample. Then we can use the empirical distribution




and calculate the P-value of the test.
Apply the modified K-S test to each of the following hypothesis testing problem:
H0 : F0j = F0j,0 vs. Ha : F0j 6= F0j,0, j = 1, 2, 3,
H0 : F1j = F1j,0 vs. Ha : F1j 6= F1j,0 j = 2, 3.
The test results are summarized in Table 4.1. The censoring rate is the ratio of the
number of censored observations to the total number of observations.
F01 F02 F03 F12 F13
n = 200
D∗n 0.0794 0.1060 0.1091 0.0975 0.1170
P-value 0.6521 0.5206 0.5157 0.6477 0.6972
censoring rate 112/200 162/200 126/200 34/88 54/88
n = 500
D∗n 0.0615 0.0683 0.1009 0.0670 0.1203
P-value 0.7639 0.5598 0.5301 0.9566 0.5933
censoring rate 262/500 371/500 367/500 103/238 135/238
n = 1000
D∗n 0.0354 0.0434 0.0495 0.0828 0.1020
P-value 0.9240 0.7164 0.7601 0.7166 0.8004
censoring rate 545/1000 747/1000 708/1000 290/455 345/455
Table 4.1: Modified Kolmogorv-Smirnov test for n = 200, n = 500 and n = 1000.
Note that all the P-values are greater than 0.1. If we set the significance level
α < 0.1, the null hypothesis of each Fij is not rejected.
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4.3.2 Chi-squared Test
There are problems using a chi-squared statistic, say, W (θ), for a goodness of
fit test. In the complete sample theory, if the unknown parameter θ is estimated by
the minimum chi-squared method or some modified minimum chi-squared method,
then as the sample size increases to infinity, the asymptotic distribution of W (θ̂)
is a chi-squared distribution. According to a Chernoff-Lehmann theorem (1954), if
the estimate θ̂ is obtained by the MLE, then W (θ̂) will not have an asymptotic chi-
squared distribution. Furthermore, under right censoring the asymptotic distribution
of a chi-squared type of test statistic depends on the censoring distribution [41]. We
finesse the difficulties by constructing a Pearson’s chi-squared statistic for checking
the goodness of fit of model Fij as follows.
There are four mutually exclusive transition paths in the irreversible model.
We can divide the patients into four categories according to their transition paths.
Let ni be the number of observed patients in category i, and Ei be the expected
number of observations in this category (calculated under the model distributions).
The chi-squared test statistic is W =
∑4
i=1(ni −Ei)2/Ei. Under the null hypothesis
that F0j = F0j,0 for j = 1, 2, 3 and F1j = F1j,0 for j = 2, 3, the test statistic W has
an asymptotic chi-squared distribution with 3 degrees of freedom.
The probabilities of the four categories p1, p2, p3 and p4 are calculated as
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follows:
(1) S0 → S1 → S2
This path implies that Y01 = min(Y01, Y02, Y03), Y12 = min(Y12, Y13). By the
independence of each Yij,















(2) S0 → S1 → S3
This path implies that Y01 = min(Y01, Y02, Y03), Y13 = min(Y12, Y13).








(3) S0 → S2
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This path implies that Y02 = min(Y01, Y02, Y03).





(4) S0 → S3
This path implies that Y03 = min(Y01, Y02, Y03).





The expected number of observations in each category under the null hypothesis is
Ei = npi.
The test results (test statistic, P-values) are summarized in Table 4.2.
Sample size n = 200 n = 500 n = 1000
W 2.05 1.42 0.14
P-value 0.5604 0.7019 0.9864
Table 4.2: Chi-squared test for n = 200, n = 500 and n = 1000.
All the P-values are greater than 0.1. If we set the significance level α < 0.1,
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the null hypothesis of each Fij is not rejected. In Table 4.2, the P-values increase
as the sample size increases. However, the P-values are random, if we repeat the
simulation and perform the hypothesis testing again, we will get different P-values.
For each sample size, we repeat the chi-squared test for 100 times and calculate the
average of the P-values. Corresponding to n = 200, 500 and 1000, the average P-
values are 0.4724, 0.4301 and 0.4638 respectively which indicates that the P-values
are stable.
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Chapter 5: Reversible Markov Multi-state Model
5.1 Introduction
In Chapter 3, we use an irreversible Markov model (Figure 3.1) in which a
patient’s transitions from relapse to treatment (S1 → S0) are not allowed. In this
chapter, we relax this restriction by allowing a relapsed patient to have the possibility
of receiving a second IST treatment. This means that a patient’s transition from S0
to S1 is reversible.
5.2 Reversible Markov Model
Similar to the model described in Chapter 3, consider a four-state stochastic
process {ξo(t), t ≥ 0} where ξo(t) is the status of a patient at time t. The four states
are the same as before:
S0: a patient is in remission immediately after IST
S1: a patient relapses after remission
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S2: a patient is dead
S3: a patient is lost to followup




Figure 5.1: Possible transition paths of a patient during the clinical trial.
Assume n individuals are participating in the clinical trial. Each of them will
take one and only one of the following possible mutually exclusive transition paths:
(1) S0 → S2
(2) S0 → S3
(3) S0 → S1 → S0 → . . .→ S2
(4) S0 → S1 → S0 → . . .→ S3
(5) S0 → S1 → S0 → S1 → . . .→ S2
(6) S0 → S1 → S0 → S1 → . . .→ S3
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Patients on transition path (3) and (4) enter S2 or S3 directly from state 0, while
patients on transition path (5) and (6) enter S2 or S3 directly from S1. We use the
same notations as in Chapter 3 except for the random variable Y1, which represents
the amount of time spent in S1 before moving to the next state. In the reversible
model, transition from S1 to S0 is allowed. Therefore, Y1 = min(Y10, Y12, Y13), where
Y10 is the random variable representing the sojourn time in S1 before moving to S0.
The observations are (Y0, δ0) and (Y1, δ1). Employing the same method in Section
3.5, we can derive the joint distribution of (Y0, δ0) and (Y1, δ1), and the formulas of














where G0(t, j) (see (3.8)) and G1(t, j) (see (3.14)) are the joint distribution functions
of (Y0, δ0) and (Y1, δ1) respectively, j = 1, 2, 3, S0 and S1 are the survival functions
of Y0 and Y1.
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5.3 Nonparametric Estimators
5.3.1 Estimators of Cumulative Hazard Functions
Suppose our observed samples are as follows:
(Y0,k, δ0,k), k = 1, 2, . . . , n,
(Y1,k, δ1,k), k = 1, 2, . . . , N01.
On the basis of (3.28) and (3.30), for j = 1, 2, 3, estimators of q0j(t) and q1j(t),














I(Y0,k ≤ t, δ0,k = j)∑n
m=1 I(Y0,m > Y0,k)















I(Y1,k ≤ t, δ1,k = j)∑N01
m=1 I(Y1,m > Y1,k)
, t ∈ [0, t1j]. (5.6)
5.3.2 Estimators of Crude Transition Probabilities
When the hazard functions qij(t) are time-dependent under some conditions,
Feller (1940) [22] proved the existence and uniqueness of the solution to the Kol-
mogorov forward equations. However, it is difficult to find an explicit form for the
solution with reversible Markov process that has time-dependent transition rates.
Except for some special cases (e.g., Yang and Chang (1990) [51]), we rely on numer-
ical methods to solve the transition probabilities.
Corresponding to the transition paths in Figure 5.1, the infinitesimal matrix
Qo(t), t > 0, of our reversible Markov model ξo is:
Qo(t) =

q00(t) q01(t) q02(t) q03(t)
q10(t) q11(t) q12(t) q13(t)
0 0 0 0
0 0 0 0
 (5.7)
Note that Qo(t) differs from that in equation (3.31) by a positive risk q10(t). The
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associated Kolmogorov forward equations are as follows:
dP o00(0, t)
dt



































= P o10(0, t)q03(t) + P
o
11(0, t)q13(t). (5.15)
Equations (5.8) and (5.9) only involve the transition probabilities P o00 and P
o
01, there-
fore form a subsystem. Once we solve (5.8) and (5.9), (5.10) and (5.11) can be solved




= f(t, y(t)), y(0) = (1, 0)T (5.16)
where










Note that the elements of the coefficient matrix A are time-dependent. Therefore
we can not solve (5.16) by eigenvalue decomposition of matrix A. We proceed with
a numerical method. We use Euler’s method which is a basic explicit method for
numerical integration of ordinary differential equations. Let h be the step size and
tn = nh. Then y





which gives an approximation:
y(tn+1) = y(tn) + hf(t, y(tn)). (5.19)
Applying equation (5.19) together with the initial value y(0) = (1, 0)T , we can obtain
an approximation of y(t) at each time tn. We can choose a smaller step size h to get
a more precise approximation.
5.3.3 Estimator of Net Survival Function
Similar to Section 3.5.3, the net survival function of a patient is:
S(t) = P (X > t | ξ(0) = 0)
= 1− P02(0, t),
where ξ = {ξ(t) : t ≥ 0} is a 3-state Markov process ({S0, S1, S2}) with the same
transition rates q01(t), q02(t), q10(t) and q12(t) as in {ξ0(t) : t ≥ 0}. The infinitesimal












q∗00(t) = −q01(t)− q02(t),
q∗11(t) = −q10(t)− q12(t).






00(t) + P01(0, t)q10(t),
dP01(0, t)
dt





= P00(0, t)q02(t) + P01(0, t)q12(t).
We solve the system of equations for the transition probabilities numerically and
obtain an estimator of P02(0, t), denoted as P̂02(0, t). Then an estimator of the net
survival function S(t) is:
Ŝ(t) = 1− P̂02(0, t). (5.21)
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5.4 Clinical Trial Terminating at a Finite Time T
In Section 5.2 and 5.3, the estimation is carried out under the assumption that
the clinical trial terminates when all the patients are dead or lost to followup, where
there is no termination date for the clinical trial. In this section, similar to Section
4.3, we will simulate the transition paths under the assumption that the clinical trial
terminates at a prespecified finite time T .
For each patient in state 0, we observe a pair of random variables (Y0, δ0), for
each patient in state 1, we observe a pair of random variables (Y1, δ1). However,
unlike the irreversible model, in the reversible model, the patients are allowed to
visit state 0 and state 1, recurrently. In this case, the distributions of the censoring
variable Y03 and Y13 depend on the number of times the patient has visited state 0
and state 1 respectively. For example, a patient has transition path 0 → 1 → 0 →
1 → 2. So initially his/her observation period from state 0 is [0, T ]. When he/she
visits state 0 for the second time, the remaining observation period from state 0 is
[Y01 + Y10, T − Y01 − Y10] given Y01 + Y10 < T . Similarly, when a patient first visits
state 1, the remaining observation period from state 1 is [Y01, T−Y01] given Y01 < T ,
when the patient visits state 1 for the second time, the remaining observation period
from state 1 is [Y01 + Y10 + Y01, T − Y01 − Y10 − Y01] given Y01 + Y10 + Y01 < T .
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Thus the length of observation period is random and the distribution depends on the
number of times the patient has visited state 0 or state 1. Therefore when estimating
Λij(0, t), we only use the observations (Y0, δ0) in state 0 after the first treatment and
the observations (Y1, δ1) in state 1 after the first relapse. In terms of observable
random variables, we have:
Y0 = min(Y01, Y02, Y03, T ), Y0 ∈ (0, T ],
{δ0 = j} = {Y0 = Y0j}, j = 1, 2,
{δ0 = 3} = {Y0 = min(Y03, T )}.
Y1 = min(Y10, Y12, Y13, T − Y01|Y01 < T ), Y1 ∈ (0, T ],
{δ1 = j} = {Y1 = Y1j}, j = 0, 2,
{δ1 = 3} = {Y1 = min(Y13, T − Y01)}.
The joint distribution of (Y0, δ0) is the same as that given in the irreversible
case (see (3.44)). But the joint distribution of (Y1, δ1) is different:




S1(u)q1j(u)du, 0 < t ≤ T, j = 0, 2,
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13(u)du, 0 < t ≤ T,
where
S1(t) = P (Y1 > t)
= S10(t)S12(t)S
∗
13(t), 0 < t ≤ T,
S∗13(t) = S13(t)F01(T − t)/F01(T ), 0 < t ≤ T,
and q∗13(t) is the hazard rate function corresponding to the survival function S
∗
13(t).
The estimators for Λij(t), i, j = 0, 1, 2, 3 can be derived in the same way as in Section




I(Y0,k ≤ t, δ0,k = j)∑n
m=1 I(Y0,m > Y0,k)




I(Y1,k ≤ t, δ1,k = j)∑N01
m=1 I(Y1,m > Y1,k)
, t ∈ [0, t1j], j = 0, 2, 3. (5.23)
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5.5 Asymptotic Distributions of the Estimators
The estimators of Λij(0, t) in this chapter are the same as those in Chapter 3.
The uniform consistency, unbiasedness, estimated variance and asymptotic distribu-
tions of Λ̂0j(0, t) for j = 1, 2, 3 and Λ̂1j(0, t) for j = 0, 2, 3 can be proved in the same
way as in Section 3.7.
The transition probabilities are calculated numerically. Therefore we do not
have a closed form for Ŝ(t) = 1− P̂02(0, t). The asymptotic distribution of Ŝ(t) can
not be derived from the asymptotic distributions of Λ̂ij(0, t). However, we can still
approximate the asymptotic distribution of Ŝ(t) using simulation.
5.6 Simulation for Reversible Markov Model
Simulations for the reversible model can be carried out similarly to that of the
irreversible model in Chapter 4. The simulation procedures are as follows:
(1) Generate the sojourn time in state 0, Y0 = y0, from the distribution function
F0(t) = 1− S0(t) using inverse transform sampling.





(3) If δ0 = 2 or δ0 = 3, stop. The observed transition path is 0→ 2 or 0→ 3, the
observed time of transition is y0. Otherwise continue to step (4).
(4) If δ0 = 1
• Generate the sojourn time in state 1, Y1 = y1, from the distribution
function F1(t) = 1− S1(t), where S1(t) = S10(t)S12(t)S13(t).
• Take a number δ1 from the set {0, 2, 3} with trinomial probabilities(
−q10(y1)/q11(y1),−q12(y1)/q11(y1),−q13(y1)/q11(y1)
)
, where q11(t) = −q10(t)−
q12(t)− q13(t).
(5) If δ1 = 2 or δ1 = 3, stop. Otherwise go to step (1).
Repeat the procedure for each of the n patients to get a sample of n independent
Markov processes, where n is the prespecified sample size. As in Section 4.1, gamma
and Weibull distributions are used to generate the Yij random variables. Additionally,
gamma(3.6, 1) is used to generate the random variable Y10. The simulations are
carried out using sample sizes 200, 500 and 1000.
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5.6.1 Estimation of the Cumulative Hazard Functions with Simulated
Date
We plot Λ̂ij(0, t) against Λij(0, t). For illustration, we display only the graphs
of Λ10(0, t) and Λ03(0, t) and their estimates in Figures 5.2 and 5.3, where Λ10(0, t)
is the cumulative hazard function of gamma(3.6, 1.0) and Λ03(0, t) is the cumulative
hazard function of Weibull(1.5, 5).
5.6.2 Estimator of the Net Survival Function with Simulated Data
The transition probabilities are solved from the Kolmogorov equations numer-
ically. We do not display the graphs for each P̂ij(0, t) separately. We only show the
graph for Ŝ(t) and compare it with the Kaplan-Meier estimator for n = 200, n = 500
and n = 1000 in Figure 5.4.
Figure 5.4 shows that the Kaplan-Meier estimator is larger than Ŝ(t) for all t >
0 and for all sample sizes. The conclusion is consistent with that in the irreversible
model in Chapter 4.
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, t > 0, α = 3.6, β = 1.0






















(a) n = 200




















(b) n = 500


















(c) n = 1000
Figure 5.2: Comparison of Λ̂10(0, t) and Λ10(0, t) for n = 200, 500, 1000, where the black line is
Λ10(0, t), the red line is Λ̂10(0, t), the blue line is the 95% confidence interval, and the green line







, t > 0, γ = 1.5, η = 5
























(a) n = 200
























(b) n = 500


















(c) n = 1000
Figure 5.3: Comparison of Λ̂03(0, t) and Λ03(0, t) for n = 200, 500, 1000, where the black line
is Λ03(0, t), the red line is Λ̂03(0, t), the blue line is the 95% confidence interval, the green line
indicates the largest uncensored observation: max(y0,k|δ0,k = 3).
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(a) n = 200, censoring rate = 89200














(b) n = 500, censoring rate = 240500














(c) n = 1000, censoring rate = 4961000
Figure 5.4: Comparison of Ŝ(t) = 1 − P̂02(0, t) and the Kaplan-Meier estimator for n = 200,
n = 500 and n = 1000. The black line represents the Kaplan-Meier estimator, the red line represents
Ŝ(t).
119
5.6.3 Clinical Trial Terminating at a Finite Time T
In this section, we carry out the simulation for a clinical trial that terminates
at a prespecified finite time T .
In the reversible model with T <∞, both Λ̂0j(0, t), j = 1, 2, 3 and Λ̂1j(0, t), j =
0, 2, 3 have larger variance compared to that when T =∞ (see Figure 5.2 and 5.3).
Because the sample size used to estimate Λij(0, t) is smaller when T < ∞. For
illustration, we display the graphs of Λ̂01(0, t) and Λ̂12(0, t) in Figure 5.5 and 5.6. We
use T = 5 in the simulation.
The transition probabilities P00(0, t), P01(0, t), P11(0, t) and P02(0, t) are cal-
culated numerically. Then an estimator of the survival function S(t) follows. We
only display the graph of Ŝ(t) and compare it with the Kaplan-Meier estimator for
n = 200, n = 500 and n = 1000 in Figure 5.7.
From the Figure 5.7, we can see that the Kaplan-Meier estimator of the survival
probability is higher than Ŝ(t) both when T = ∞ and T = 5. It indicates that the
Kaplan-Meier estimator may overestimate the survival probability because it does
not use the data on relapse. The conclusion is consistent with that in the irreversible
model.
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, t > 0, α = 2.6, β = 0.8





















(a) n = 200, censoring rate = 114200



















(b) n = 500, censoring rate = 248500

















(c) n = 1000, censoring rate = 5341000
Figure 5.5: Comparison of Λ̂01(0, t) and Λ01(0, t) for n = 200, 500, 1000. The black line is Λ01(0, t),
the red line is Λ̂01(0, t), the blue lines are the 95% confidence interval when T = ∞, the orange
lines are the 95% confidence interval when T = 5, the green line indicates the largest uncensored







, t > 0, γ = 1.5, η = 4























(a) n = 200, censoring rate = 6286















(b) n = 500, censoring rate = 168252















(c) n = 1000, censoring rate = 313466
Figure 5.6: Comparison of Λ̂12(0, t) and Λ12(0, t) for n = 200, 500, 1000. The black line is Λ12(0, t),
the red line is Λ̂12(0, t), the blue lines are the 95% confidence interval when T = ∞, the orange
lines are the 95% confidence interval when T = 5, the green line indicates the largest uncensored
observation when T =∞, the pink line indicates the largest uncensored observation when T = 5.
122














(a) n = 200, censoring rate = 89200 when
T = ∞, censoring rate = 112200 when T = 5














(b) n = 500, censoring rate = 240500 when
T = ∞, censoring rate = 306500 when T = 5














(c) n = 1000, censoring rate = 4961000 when
T = ∞, censoring rate = 6091000 when T = 5
Figure 5.7: Comparison of Ŝ(t) = 1− P̂02(0t) and the Kaplan-Meier estimator when T =∞ and
T = 5 for n = 200, n = 500 and n = 1000. The black solid line is the Kaplan-Meier estimator when
T = 5, the black dashed line is the Kaplan-Meier estimator when T =∞, the red solid line is Ŝ(t)
when T = 5, the red dashed line is Ŝ(t) when T =∞.
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5.7 Hypothesis Testing
5.7.1 Modified Kolmogorov-Smirnov Test
The hypothesis tests are carried out in a similar way to that in Section 4.3.1
for irreversible model. We only show the testing results as given in Table 5.1.
F01 F02 F03 F10 F12 F13
n = 200
D∗n 0.0755 0.0805 0.0873 0.1020 0.0797 0.1817
P-value 0.6722 0.6642 0.6132 0.1828 0.5458 0.6943
censoring rate 127/228 168/228 161/228 58/86 55/86 59/86
n = 500
D∗n 0.0504 0.1031 0.0754 0.0763 0.0826 0.1083
P-value 0.6823 0.3610 0.8382 0.4310 0.4489 0.7639
censoring rate 325/570 429/570 386/570 148/218 129/218 159/218
n = 1000
D∗n 0.0366 0.0566 0.0411 0.0507 0.0449 0.0965
P-value 0.8932 0.8686 0.8920 0.5904 0.8434 0.8934
censoring rate 616/1159 871/1159 831/1159 297/456 283/456 332/456
Table 5.1: Modified Kolmogorv-Smirnov test for n = 200, n = 500 and n = 1000.
Note that all the P-values are greater than 0.1. If we set the significance level
α < 0.1, the null hypothesis of each Fij is not rejected.
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5.7.2 Chi-squared Test
The chi-squared test is performed a little different from that in Chapter 4
for irreversible model. We use the same test statistic W =
∑m
i=1(ni − Ei)2/Ei,
but the choices of categories are different. In the irreversible model, there are four
possible transition paths so we consider each transition path as one category. In
the reversible model, the number of possible transition paths is infinite. We can
combine different transition paths to form a single category. For example, we can
divide the observations into the following four categories: (A) transition paths of
length two ending in S2 (death), (B) transition paths of length two endings in S3
(loss to followup), (C) transition paths of length three, (D) transition paths of length
not less than four. The probabilities of falling into each of the four categories are:
(1) S0 → S2
p1 = P (falling into (A))






(2) S0 → S3
p2 = P (falling into (B))





(3) S0 → S1 → S3 or S0 → S1 → S2
p3 = P (falling into (C))
= P (Y01 = min(Y01, Y02, Y03))
(













where S1(t) = S10(t)S12(t)S13(t).
(4) The others.
p4 = P (faling into (D))
= 1− p1 − p2 − p3.
The test results (test statistic and P-values) are summarized in Table 5.2. All
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Sample size n = 200 n = 500 n = 1000
W 3.00 1.59 0.62
P-value 0.2690 0.2435 0.8931
Table 5.2: Chi-squared test for n = 200, n = 500 and n = 1000.
the P-values are greater than 0.1. Therefore if we set the significance level α < 0.1,
the null hypothesis of each Fij is not rejected. In Table 5.2, as the sample size
increases, the P-values increase in general. However, the P-values are random. If we
repeat the simulation and perform the hypothesis testing again, we will get different
P-values. We repeat the simulations for 100 times and for each sample size, we
calculate the mean of 100 the P-values. Corresponding to n = 200, 500 and 1000,
the average P-values are 0.4615, 0.5223 and 0.4964 respectively which indicates that
the P-values are stable.
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Chapter 6: Conclusion
In a fundamental paper, Fix and Neyman (1951) [23] introduced a method
for estimating the survival function with right-censored survival time data collected
from clinical trials. The method takes into account of the available data on each
patient’s status with regard to relapse, recovery, loss to follow-up and death. A
patient’s survival time is measured from a well-defined starting time such as the
time of diagnosis to the time of death or loss to followup and it includes the sojourn
times that the patient spends in various states. Fix and Neyman constructed an
absorbing Markov process to model the observable data on the disease evolution of
a patient during a clinical trial. Taking into consideration of right-censored Markov
model, Fix and Neyman introduced a procedure to calculate the model survival
function as well as its estimator. The Fix-Neyman model is a homogeneous Markov
process, i.e., transition rates are independent of time. In this thesis, we generalize
the Fix-Neyman method for nonhomogeneous Markov models, i.e., the transition
rates are both time and state dependent. From which one can estimate the survival
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function nonparametrically. This problem is raised in Yang (2013) [50] and becomes
the topic of this thesis. Although finite nonhomogeneous Markov model for lifetime
analyses has been used widely in more recent years, Fix-Neyman’s method is hardly
used except mostly in Chiang’s work (e.g., Chiang (1968) [14]) and by his students.
In this thesis, the model survival function is calculated by solving a system
of Kolmogorov forward equations. Dictated by the availability of closed form so-
lutions, the Markov models for statistical analyses are investigated separately for
the irreversible and reversible models. Analytical solutions for the survival function
can be derived for irreversible models. We use the 4-state Markov model with two
transient and two absorbing states to demonstrate the derivations and estimate the
cumulative hazard functions and survival function. In the reversible models, except
in some special cases, analytical solutions are not available. In this thesis, numerical
solutions are developed for statistical analyses.
The generalization of the Fix-Neyman model includes a number of existing
multi-state models for right-censored lifetime data as special cases, such as the mul-
tiple decrement models, the illness and death models, the staging models, and the
classical right censoring model. The optimality of the celebrated Kaplan-Meier non-
parametric estimator of the survival function is based on the classical right censoring
model. Thus the generalization of the Fix-Neyman model and their procedure unify
129
the estimation of the survival function with right-censored data. In general, the
Fix-Neyman model utilizes more of the available data in the clinical trial than that
of the classical right-censoring model which disregards patient’s status data in the
clinical trial.
Extensive simulations of the Markov models for both irreversible and reversible
cases are carried out to examine the accuracy and distributional properties of the
estimators. Using the Markovian property, simulated data are obtained by simulating
a sequence of competing risks models at each transition time. With simulated data,
a comparison is made between the estimated survival function under a particular
4-state model and the Kaplan-Meier estimator under a 3-state model (which ignores
the status data). The comparison shows that the Kaplan-Meier estimator has larger
values for all times and in all cases of comparisons.
Future work includes studying of power functions of various goodness of fit
tests, and determining under what conditions would the Kaplan-Meier estimator be
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